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1. SUMMARY 
Gene therapy is a promising treatment option for cancer. Ideally, a therapeutic 
gene is delivered specifically into tumor cells sparing the neighboring normal cells. 
For this purpose gene delivery vectors are designed that can recognize structures, 
which are exclusively expressed on tumor cells (i.e. the tumor-associated antigens 
-TAA-). Retroviral vectors are commonly used for gene therapy by modifying the 
envelope protein responsible for the recognition of the target cell. The Vesicular 
Stomatitis Virus G protein (VSV-G) is a well-liked choice for pseudotyping the 
retroviral vectors since it confers on the viral particle stability to allow concentration 
to high titers necessary for the clinical applications. However, the main drawback 
of VSV-G, the ubiquitously expressed receptor and thus the broad target range, 
hinders the use of this protein for targeted gene therapy.  
In this thesis, we aimed to modify the VSV-G for targeted gene therapy against 
Prostate Stem Cell Antigen (PSCA) -expressing tumors. Therefore we followed 
two approaches. The first approach comprised of the fusion of a single-chain 
antibody fragment against PSCA to the N-terminus of VSV-G. In the second 
approach the VSV-G was modified by insertion of a small epitope. 
We could demonstrate that two positions in the N-terminal region of VSV-G protein 
permit insertion of a ten amino acid long epitope. These mutant VSV-G proteins 
were successfully assembled into retroviral particles. We demonstrated that the 
mutant retroviral particles can be used for targeting to PSCA-positive cells using 
nanobeads. The nanobeads were chemically coupled to antibodies against the 
epitope in the VSV-G protein and PSCA on the tumor cell. These bispecific 
nanobeads allowed the recruitment of mutant retroviral particles to the PSCA-
positive cells. Our results point out the potential of these mutant retroviral particles 
in targeted gene delivery. Further studies will be necessary to assess the 
efficiency of in vivo targeted gene therapy using these mutant retroviral particles. 
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2. INTRODUCTION 
2.1. Gene Therapy 
Gene therapy is a molecular approach in medicine whose aim is to cure or slow 
down the progression of a disease by transferring genetic material into specific 
cells. Among the first candidates for gene therapy were the monogenic diseases, 
where the delivery of a functional gene copy substitutes for a defective gene. 
Accompanied by increased knowledge of the molecular mechanisms underlying 
diseases, several other target diseases also entered the scene of gene therapy, 
including infectious diseases and cancer. The first clinical gene transfer trial 
comprised marker gene transfer to tumor-infiltrating lymphocytes (TILs) in 1989 
[4]. In this first study, TILs were isolated from patients and a bacterial Neomycin 
resistance gene was transferred by a retroviral vector into these cells. Gene-
marked TILs were re-infused into patients and the fate of engineered cells was 
observed by subsequent periodic blood sampling from patients. This study was 
followed by several other gene marking studies [5] . It was in 1990 when Blaese et 
al. conducted the first therapeutic gene therapy trial on two girls suffering from 
adenosine deaminase (ADA) deficiency – a form of severe combined immune 
deficiency (SCID). ADA deficiency is an inherited genetic disorder which leads to 
inability to degrade adenosine. This in turn causes toxicity to T cells and results in 
immunodeficiency. In this trial both patients received infusions of autologous gene-
corrected T lymphocytes. The clinical outcomes of this study were encouraging 
[5,6].  
Currently, nearly thousand clinical gene therapy protocols are applied worldwide 
[7]. And surprisingly the initial targets, monogenic diseases, constitute only a small 
fraction of the diseases treated by gene therapy approaches (Figure 1A) [1]. Most 
of the protocols (67%) intend to treat cancer, which reflects both the urgent need 
for new cancer treatment modalities and also the already existing knowledge of 
the disease biology. In general, cancer gene therapy trials employ three 
approaches to eliminate tumor cells. The first approach aims at boosting the 
patient’s immune system to recognize and defeat tumor cells. Here, tumor cells 
can be modified to express molecules that enhance an anti-tumor immune 
response. Several molecules have been used so far, including tumor-specific 
(TSA) or tumor-associated (TAA) antigens and cytokines. To date, Interferon (IFN) 
γ [8] and Interleukin (IL)-2 [9,10] encoding genes are used in the treatment of 
several cancers, such as prostate cancer, melanoma and lymphoma (Figure 1B).  
The second strategy aims at destroying tumor cells by facilitating a cell cycle 
arrest or by inducing programmed cell death (apoptosis). Most cancer cells bear 
defects in tumor suppressor genes, which control the cell cycle and the apoptosis. 
Therefore, it is possible to eliminate tumor cells by delivering into tumor cells 
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genes whose products either restore the function of a tumor suppressor gene such 
as p53 or induce apoptosis.  
The third approach for treating cancer by transfer of genes is the so-called suicide 
gene therapy. Here, genes encoding enzymes, such as the thymidine kinase (TK) 
of the Herpes Simplex Virus (HSV), are transferred into tumor cells. The modified 
tumor cells become capable of phosphorylating the prodrug ganciclovir, which can 
be administered intratumorally or systemically. This initiates a phosphorylation 
cascade whose end product triphosphate ganciclovir is a toxic nucleoside 
analogue, which interferes with the DNA replication [11].  
Gene therapy is an up-and-coming option for many hereditary and infectious 
diseases as well as cancer, and yet incurable diseases such as AIDS. Although 
the preferential methods may vary for each disease, all gene therapy applications 
share the common requirement for a delivery vehicle that ensures a selective and 
highly efficient gene transfer into the target cells.  
 
Distribution of (A) indications addressed by the gene therapy clinical trials and (B) the therapeutic 
genes transferred (http://www.wiley.co.uk/genmed/clinical/). 
 
 
Figure 1. Gene therapy clinical trials 
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2.2. Gene Therapy Vectors 
The main objective of the gene therapy is to transport therapeutic genetic material 
into the target cells. Accordingly, gene transfer vehicles, so-called vectors, are 
needed. An ideal gene therapy vector should allow selective and efficient transfer 
of a gene. Furthermore, it should be easy to handle and cost-effective to produce, 
and last but not least, it should cause no adverse immune responses in the host 
[12].  
2.2.1. Non-viral vectors 
Gene delivery vectors can be broadly categorized into two groups: non-viral and 
viral vectors. Non-viral vectors are appealing since they are non-infectious, and 
are not very toxic to the cells. They can be easily prepared and produced at large 
scales. The size of the genetic material that can be transferred using a non-viral 
vector is theoretically unlimited, whereas in the case of viral vectors the packaging 
capacity is defined. Another advantage of non-viral vectors compared to the viral 
gene transfer systems is their safety. In general, the non-viral vectors do not 
induce a specific immune response and are usually less immunogenic than viral 
vectors. However, the low gene transfer efficiency achieved with non-viral vectors 
remains an obstacle for clinical applications. 
The simplest way of transferring DNA into a cell is to inject naked DNA. Naked 
DNA was shown to be taken up by muscle cells but the transfection efficiency was 
low [13,14]. Moreover, expression of the transgene was transient. Genetic material 
transfer using non-viral vectors can also be performed by chemical or physical 
methods [15]. The physical transfection methods include electroporation [16-18] 
and gene bombarding [19]. Electroporation relies on the generation or opening of 
pores on the target cell membrane by electrical shock, followed by the entry of the 
DNA into the cells. In gene bombarding the DNA, which is coupled to gold 
particles, is ‘shot’ into the target cells under high pressure. Chemical transfection 
methods include calcium phosphate precipitation [20]. In calcium phosphate 
precipitation [21], [4-(2-hydroxyethyl)-1-piperazine]-ethanesulfonic acid (HEPES) -
buffered solution containing phosphate ions is used together with calcium chloride 
to form complexes with DNA. Calcium phosphate/DNA complexes precipitate onto 
the monolayer cells in culture.  
DNA can also be delivered using lipids and polymers. These DNA packages are 
internalized by the target cell via the endocytotic pathway. Anionic and neutral 
liposomes have been used for DNA transfer, but are now outnumbered by cationic 
liposomes [22-28]. Cationic liposomes can interact with the negatively charged 
DNA and form complexes spontaneously. Cationic liposome/DNA complexes still 
bear absolute positive charges that protect the DNA from degradation by enzymes 
and interact with the negatively charges phospholipids in the target cell membrane 
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and release their contents into the target cells [29-31]. Alternatively, cationic 
polymers can be formed into complex with DNA for delivery [32]. The most 
commonly used cationic polymers are poly-L-lysine (PLL) and its derivatives 
polyethylenimine (PEI) [33-36], polybrene and chitosan [37-39]. Cationic polymers 
are synthetic molecules and therefore can be readily modified for ligand-targeted 
binding to defined cell types [40,41]. 
Despite the safety advantage of non-viral vectors, their gene transfer efficiency 
must be improved to become ideal gene therapy vectors. Actually, most studies 
and clinical trials [7] focus on viruses as gene delivery vehicles (Figure 2). Viruses 
have naturally evolved to transfer genes into host cells. Adenoviruses, Herpes 
Simplex viruses, Adeno-associated viruses and retroviruses (including 
lentiviruses) are among the most commonly used viruses in gene therapy. 
 
2.2.2. Viral vectors 
During evolution viruses have acquired advanced mechanisms to deliver their 
genetic material to their host cells such as the ability to overcome cellular barriers 
(i.e. the plasma membrane, and degradation by lysosomes after internalization). 
Therefore, viruses offer great opportunities in the gene therapy field, where 
efficient gene delivery plays a decisive role [42] . There are several viruses which 
have been adopted for gene therapy. 
2.2.2.1. Adenoviruses 
Adenoviruses (Ad) are non-enveloped, linear double-stranded DNA viruses. An 
approximately 36kb long adenoviral genome is encapsulated in an icosahedral 
protein coat. Adenovirus entry into the host cell is mediated by two main 
interactions. The knob domain of the 182 kDa fiber protein in the viral coat 
Figure 2. Gene therapy vectors used in clinical trials [1]. 
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interacts with the “Coxsackie and Adenovirus receptor” (CAR) in the target cell 
[43-45]. Virus internalization occurs by means of receptor-mediated endocytosis 
via the interaction between Arg-Gly-Asp motives in the penton base and the 
cellular integrins [46,47]. Adenoviruses can infect both dividing and non-dividing 
cells with equal efficiency. Also, recombinant adenoviruses can be produced at 
very high concentrations and they have a high capacity for foreign DNA 
(approximately 8.5kb). However, adenovirus-mediated therapeutic gene 
expression is transient since no integration into the host genome takes place. 
Adenoviruses have been extensively used in various gene therapy approaches 
and are under continuous development [48,49]. Three generations of adenoviral 
vectors have been generated to decrease the cytopathic effects and immune 
responses. The first-generation adenoviral vectors lack the E1 region, whose 
products control the activation of DNA synthesis and the late viral gene expression 
[50]. These E1-deleted adenoviral vectors are replication-deficient, but are still 
immunogenic. To reduce the adverse immunological effects of adenoviral vectors 
the second-generation adenoviral vectors were generated by deleting the E2 or E4 
region from the E1-deleted viruses [51-54]. Further improvement has been 
attempted with the so-called “gutless” vectors (third-generation) which retain only 
the cis-acting inverted terminal repeats and a packaging signal from the wild-type 
virus [55]. Production of gutless vectors requires a complementing packaging cell 
line [56-59] or a helper virus [60-62], which provides the necessary viral structural 
proteins in trans.  
A limitation of adenoviruses as gene therapy vectors is that the majority of the 
human population already has faced infections with wild-type adenoviruses. 
Therefore, the presence of neutralizing antibodies against different serotypes 
remains an obstacle for gene therapy using adenoviral vectors. Nevertheless, 
adenoviral vectors constitute the most commonly used vectors in clinical gene 
therapy trials (Figure 2) [63-68]. 
2.2.2.2. Adeno-associated viruses 
Adeno-associated virus (AAV) – a member of the parvovirus family- is a single-
stranded non-enveloped DNA virus with a 4.5 kb genome. Usually the AAV 
serotype 2 is used as a template for AAV vectors. Wild-type AAV 2 is non-
pathogenic to humans and integrates into the long arm of chromosome 19 in 
human cells [69,70]. However, the recombinant AAV (rAAV) loses this specificity 
and integrates at other sites [71]. All but 145bp of the AAV genome, the terminal 
repeats containing a promoter, can be removed to insert foreign genes, yet the 
AAV genome size may not be exceeded. Unfortunately, this packaging capacity is 
often too small for therapeutic genes, limiting the applications of rAAV as gene 
therapy vector. AAV-derived vectors require a helper virus (mostly Ad) for viral 
replication. Difficulties in complete removal of the helper virus from the viral stocks 
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still hinders the use of AAV-derived vectors for human gene therapy [72]. 
Nonetheless, rAAV vectors have been introduced into the Phase I clinical trials in 
cystic fibrosis treatment [73,74] delivering the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene. These studies demonstrated that AAV-
derived vectors were well tolerated by the patients. On the other hand, a patient 
died in a Phase I trial using rAAV to deliver Hemophilia B (Factor IX) through 
intrahepatic artery [75] and the study was abandoned. This incident led to some 
apprehensions about the safety of rAAV-mediated gene therapy. 
2.2.2.3. Herpes Simplex Virus-1 
Herpes Simplex Virus-1 (HSV-1) is a natural human pathogen with a 150kb 
double-stranded DNA genome. Non-essential genes can be removed and the 
virus can then carry up to 50kb of foreign genes, which enables several genes to 
be packaged [76]. HSV-1 infection has two phases: the lytic replication and the 
latent state. The lytic infection, which generally takes place in epithelial cells, 
results in virus replication and lysis of the host cell, hence the name. However, 
sometimes the virus proceeds along the nerves and commences the latent state in 
the neurons. The latent virus shuts off the host cell protein synthesis and allows 
the production of only a small set of RNA species (Latency-Associated Transcripts 
or LATs) [77-80]. 
HSV-1 can infect both dividing and non-dividing cells but integration into the host 
genome does not occur. Although it can infect a broad range of cells, HSV exhibits 
a natural tropism to neurons, where it can persist as an intranuclear episome 
during the lifetime of the host. A disadvantage of HSV-1–derived vectors is their 
cytotoxicity owing mainly to proteins called “the infected cell proteins” (ICP) [81]. 
Recombinant HSV-1 vectors are produced with deletions in the ICP genes to 
reduce toxicity. The biggest concern in the use of HSV-1 vectors for human gene 
therapy is the safety of this natural pathogen.  
There are two generations of HSV-1 vectors. The first-generation vectors contain 
mutations in a single gene and can replicate only in dividing cells. For instance, 
HSV1716 is a first-generation vector in which one copy of the ICP34.5 gene is 
deleted. ICP34.5 is normally found as two copies located in the inverted repeat 
regions and plays an important role in pathogenicity in neurons. HSV1716 is used 
in clinical trials for recurrent high-grade glioma, where viral replication was shown 
to take place only in glioma cells [82]. To further reduce the risk of reverts to the 
wild-type virus, in the second-generation vectors more genes are deleted or 
mutated. G207 is a second-generation HSV-1-derived vector in which both copies 
of ICP34.5 are deleted and a lacZ marker gene is inserted destructively into the 
gene encoding the large subunit of viral ribonucleotide reductase. It has been 
tested in malignant glial tumors and exhibited anti-tumor effects without any virus-
related toxicity [83].  
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2.2.2.4. Retroviruses 
Retroviruses [42,84-88] are enveloped, single-stranded positive-sense RNA 
viruses with a diploid genome (Figure 3). Retroviruses are divided into two groups 
according to the complexity of their genomes: simple (e.g. Murine Leukemia Virus 
–MLV) and complex retroviruses (e.g. Human Immunodeficiency Virus –HIV). All 
retroviruses contain at least three coding regions – gag, pol and env (Figure 4). 
The gag (group-specific antigen) region encodes a precursor protein, which gives 
rise to the capsid (CA), the matrix (MA) and the nucleocapsid (NC) proteins. The 
pol gene (which overlaps at the 3’ end with the 5’ end of gag) encodes for the 
reverse transcriptase, which generates a DNA copy of the RNA genome, and the 
integrase, the enzyme catalyzing the integration of the provirus into the host 
genome. The product of the third region env is the envelope protein, which 
consists of a surface subunit (SU) and a transmembrane (TM) subunit. Moreover, 
there is a small coding region called pro, common to all retroviruses, coding for the 
protease that is responsible for the cleavage of the viral proteins. Complex 
retroviruses, such as Human T Cell Leukemia Virus (HTLV) or HIV, contain 
additional coding regions for accessory proteins which enable them to infect post-
mitotic or quiescent cells. 
 
 
The retrovirus-derived vectors are generated by the removal of non-essential 
coding regions from the virus genome. The essential gag-pol and env regions can 
be supplied in trans. To reduce the reversion to the wild-type replication-
competent retrovirus, these essential coding regions are supplied on different 
transcriptional units. The only sequences necessary in cis are the packaging 
signal (Ψ), the long-terminal repeats (LTRs) and the elements directing the reverse 
Figure 3. Structure of a retrovirus. 
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transcription such as the primer-binding site. LTR regions exist as two copies, 
each on one side of the viral genome and contain the promoter elements that 
regulate the transcription of the genes and regions responsible for the 
polyadenylation of proviral transcripts. Removal of the non-essential genes allows 
packaging of approximately 7-8kb foreign DNA.  
 
A: The genome structure of a prototypical retrovirus. B: cis-acting elements of a typical retroviral 
vector. Modified from Buchschacher, G. L. and Wong-Staal F. 2000 [89]. 
The natural tropism of retroviruses is defined by the envelope protein. In general, 
the envelope proteins consist of two subunits. The surface subunit (SU) binds to 
the target cells via its receptor and brings the transmembrane unit (TM) into the 
vicinity of the cell membrane. Then, the TM subunit mediates fusion of the 
retroviral envelope with the target cell membrane. Target specificity can therefore 
be manipulated by modifying the SU portion. Moreover, viral particles can be 
assembled using the envelope protein from another virus [90-92]. Although several 
viral envelope proteins have been used to alter the retroviral tropism, most of the 
studies concentrated on Vesicular Stomatitis Virus G protein (VSV-G) [93]. VSV-G 
confers a broad target range [94] and stability on the retroviral particle, paving the 
way for the concentration of the virus to high titers by ultracentrifugation [95]. 
Retroviral vectors are the prototype viral vectors used in human gene therapy [96]. 
The results of the first trial encouraged further work with retroviral vectors and a 
few years later retroviral vectors were used to treat a lethal form of Severe 
Combined Immune Deficiency (X-linked SCID) [97-100]. The outcomes were 
auspicious, yet three of the patients developed T-cell leukemia-like symptoms 
[101]. Careful analysis of the proviral integration sites in these patients revealed a 
single copy of provirus integration at or near the Lim domain only-2 (LMO-2) gene 
[102], whose gene product is a central regulator of hematopoiesis. This led to 
concerns about the insertional mutation risk in the retroviral gene delivery. 
Figure 4. Genomic organization of retroviruses and retroviral vectors. 
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Nevertheless, retroviruses continue to make up 24% of the clinical protocols used 
in human gene therapy.  
2.3. Targeting retroviral gene delivery vectors 
An essential feature of an ideal gene therapy vector is the ability to distinguish 
between target (e.g. tumor cells) and non-target cells. There are mainly two steps 
in gene delivery that may be modified to achieve a targeted tropism. One way is to 
control expression of the therapeutic gene at the transcriptional level by making 
use of tissue- or tumor-specific promoters so that the delivered gene is only 
expressed in target cells [103,104]. For instance, Vile et al. [104] demonstrated 
successfully that melanoma cells can be targeted with retroviral vectors under the 
transcriptional control of the murine tyrosinase gene promoter region. Another 
approach to achieve targeted gene delivery into the target cells is to re-define the 
viral host range [105-107], thus the virus can only infect a selected cell type while 
leaving the neighboring non-target cells untouched.  
2.3.1. Modification of the viral envelope proteins for targeted gene therapy of 
tumor cells 
Promising target structures for the selective transduction via modified viruses are 
the so-called “tumor-associated antigens (TAA)” (i.e. HER2/neu on mammary 
carcinoma cells, the high-molecular-weight melanoma-associated-antigen (HMW-
MAA) on malignant melanoma cells). Ideally, these antigens are exclusively 
expressed on the tumor cells.  
Target cell tropism can be achieved by several genetic modifications of the viral 
envelope proteins, for example by introducing engineered domains derived from 
growth factors, domains from adhesion molecules and other targeting devices 
such as single-chain variable fragments (scFv). In a recent approach Ohno et al. 
[106,107] modified the Sindbis virus envelope protein by inserting two tandem 
repeats from the immunoglobulin G-binding domain (ZZ-domain) of Protein A from 
Staphylococcus aureus. After conjugating chimeric viruses with monoclonal 
antibodies against CD4 and EGFR, respectively, selective infection of CD4-
positive lymphoblastoid cells and EGFR-positive glioma cells were obtained. The 
ZZ-domain was also used to modify the ecotropic and the amphotropic Moloney 
Murine Leukemia Virus (MoMuLV) envelope proteins. When tethered to an anti-
HER2 monoclonal antibody these chimeric viral particles specifically bound to 
HER2/neu-positive cells. However, the fusion capacity of the chimeric envelope 
protein was severely impaired. Therefore, it was necessary to co-express the wild-
type envelope protein [108]. Recently, Morizono et al. [109] used a ZZ-domain-
modified Sindbis virus envelope protein to pseudotype lentiviruses. The lentiviral 
particles were conjugated to anti P-glycoprotein antibodies. Then the conjugated 
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chimeric lentiviral particles were successfully used for selective in vivo 
transduction of melanoma cells. The IgG-binding domain allows this system to be 
extended with other antibodies targeting a broad spectrum of cell types. On the 
other hand, a clinical application in humans can be hindered by a variety of IgG 
antibodies present in human serum that likely compete with the binding of the 
conjugated targeting antibody. An alternative approach to confer target specificity 
and to avoid interference with serum antibodies is the direct fusion of a single-
chain variable fragment to the viral envelope protein. Following this approach, 
Martin et al. [110,111] modified the amphotropic 4070SU protein by fusing a 
single-chain antibody fragment against the high-molecular-weight melanoma-
associated-antigen (HMW-MAA) expressed on melanoma cells. They introduced a 
matrix metalloprotease (MMP) cleavage site between the scFv and the envelope 
protein. The modified viral particles bound to the melanoma cells and the MMP 
enzymes on the target cell surface cleaved off the scFv. The virus was then free to 
transduce the target cell. Although a successful binding of the viral particles to 
melanoma cells was demonstrated, the transduction efficiencies were not 
convincing.  
2.3.2. Pseudotyping retroviral vectors 
A widely used approach for targeting viral vectors to specific cell types or to 
expand the tropism is to exchange the envelope proteins. This procedure, the so-
called pseudotyping, allows adopting the known tropism of a certain virus. To date, 
several envelope proteins have been tested for altering the tropism of retroviral 
vectors [112-114], in particular, the Gibbon Ape Leukemia Virus (GALV) [113-115] 
envelope protein and the VSV-G protein [93,95,116-119]. Although some studies 
suggest GALV envelope protein as a promising alternative [120-122] to VSV-G 
due to comparable transduction efficiencies and the identified cellular receptor, 
VSV-G continues to be the leading choice for pseudotyping retroviral particles 
[123].  
2.3.2.1. Vesicular Stomatitis Virus G protein (VSV-G) 
The VSV-G protein from Indiana serotype contains 511 amino acids, and is a 
Type-I membrane protein [124]. This envelope protein possesses a single 
transmembrane domain and exposes its amino terminus on the exterior side of the 
membrane and its carboxy terminus on the interior side.  
During maturation, the VSV-G precursor first inserts into the Endoplasmic 
Reticulum (ER) where the signal peptide is cleaved and the protein trimerizes 
[125,126]. Most of the folding and also the N-glycosylations occur at this step while 
the protein is still in the ER [127]. Only the correctly folded, glycosylated [128,129], 
and trimerized proteins are transported to the Golgi apparatus. Misfolded VSV-G 
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proteins are retained in the ER associated with ER chaperons like BiP and 
calnexin [130-132]. In the Golgi apparatus the post-translational modifications are 
further processed and the VSV-G protein is transported to the cell membrane. 
There is a very tight regulation on the transport of the protein [126]. Therefore, any 
modification to target the VSV-G to a specific receptor must maintain three 
features of the protein. First of all, the proper folding must be retained. Second, the 
trimerization must take place. Last but not least, a vital step in the viral infection, 
the fusion capacity, must be preserved despite the mutation. 
VSV-G-mediated viral infection starts with the binding of VSV-G protein to its yet 
unidentified ubiquitously expressed cellular receptor [124]. It has been shown by 
saturation experiments in Vero cells that VSV-G facilitates the viral entry over a 
specific receptor [133]. Schlegel et al. proposed phosphatidylserine (PS) as the 
cellular receptor since purified PS inhibited VSV binding and infection [134]. 
However, Coil et al. [135] reported being unable to reproduce these results. A 
following study from Carneiro et al. [136] confirmed a direct interaction between 
VSV-G and PS before the acidification in the endosomal vesicle, but did not point 
out PS as the cellular receptor. Using the information from other Rhabdoviruses 
that are known to bind to PS, a similar PS-binding domain (called the p2-like 
peptide) is located in VSV-G between the amino acid residues 134 and 161 [137-
139].  
Following the interactions with the receptor, virus is internalized into endosomal 
vesicles, which shortly thereafter acidify. The acidic pH triggers drastic 
conformational changes in the VSV-G protein and generates a fusion-active form 
[140-142]. VSV-G-mediated fusion of the viral envelope with endosomal 
membrane occurs in a narrow pH range, between 5.8 and 6.2. Histidine residues 
148 and 149 are protonated in this pH range and these positively charged 
residues were shown to interact with PS [136,141]. All viral fusion proteins 
including VSV-G share some characteristics [143,144]. There are two main 
classes of viral fusion proteins: Class-I proteins (such as Influenza HA) and Class-
II proteins (such as the Alphavirus E1 protein). These two classes differ in the 
number of units in the envelope oligomers and in the initial fusion step. The Class-I 
proteins form trimers of two-chain monomers whereas the Class-II proteins exist 
as dimers and are associated with another viral protein. In Class-I proteins the 
fusion peptide is generated by proteolytic cleavage of the N-terminus of the 
protein, however Class-II proteins are not cleaved – rather their associated 
proteins are. Despite all the structural differences between the classes, both types 
of proteins are synthesized in an energetically metastable conformation favoring 
the post-fusion conformation (irreversible conformational change). Another 
common property of both fusion protein classes is the post-fusion structure, which 
appears as trimers. The VSV-G protein, despite sharing several features with 
already defined viral fusion proteins, has some distinct characteristics [145]. It 
forms like the Class-I fusion proteins trimers in the viral membrane, but is not 
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synthesized in metastable conformation and the conformational change leading to 
fusion is reversible.  
Fusion of the endosomal membrane with the viral envelope, releases the viral 
capsid into the cytoplasm. The viral genome is then transported to the nucleus and 
the viral genes are expressed. 
The VSV-G is a common choice to extend the tropism of retroviral vectors and to 
improve particle stability. However, for clinical applications of VSV-G-pseudotyped 
retroviral particles the tropism must be restricted to defined target cell populations. 
In recent years, efforts were made to identify regions in the VSV-G protein that 
could be modified without affecting protein function but on the other hand could be 
useful for altering the tropism of the retroviral particle [146,147]. Yet, most of the 
introduced modifications affected the function of the VSV-G protein negatively: 
Mutations in the ectodomain were reported to interfere with intracellular transport, 
whereas many of the transmembrane mutants fail to induce fusion [126,148]. N-
terminal fusion of a single-chain antibody fragment to the VSV-G retained the 
intracellular transport capacities of the wild-type protein, but the fusion and in turn 
the transduction efficiency was inefficient [149]. Recently, a study reported 
successful incorporation of His-tag into the ectodomain of VSV-G in a transposon-
based procedure [150]. One of the insertions was made at amino acid position 24 
(precursor peptide) and the modified protein was successfully incorporated into 
retro- and lentiviral particles. Interestingly, Guibinga et al. [146] showed that VSV-
G mutant with an insertion of ten amino acid-long collagen binding domain at this 
position displays a temperature-sensitive phenotype. The mutant was transported 
to the surface of transfected cells only at permissive (30°C) temperature. Taken 
together these results emphasize the need of deeper understanding of the VSV-G 
structure. 
2.3.3. Nanoparticles as targeted therapy tools 
Still in its infancy, the nanotechnology offers invaluable tools for the targeted gene 
delivery. Nanoparticles may be composed of gold, silica or iron oxide cores 
[26,151-154]. Surface of the nanoparticles are generally modified to enhance DNA 
or vector binding and the complex stability. The molecules used commonly to 
surface-modify nanoparticles include among others polysaccharides, starch, 
dextran and oleic acid (www.chemicell.de ). 
Iron oxide-derived magnetic nanoparticles are of special clinical interest when the 
gene delivery vehicle or the genetically engineered targets cells are to be 
concentrated or purified. Chan et al. [155] made use of the ability of lentiviruses to 
capture packaging cell surface proteins during budding. The packaging cell 
surface was biotinylated, and the lentiviruses labeled with biotin were concentrated 
with streptavidin-coupled magnetic beads. The virus was concentrated up to 102-
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103 fold depending on the type of the envelope protein used (VSV-G or the 
amphotropic envelope proteins, respectively). The authors have also has 
engineered HEK 293T packaging cells to express B7.1 (CD80) on the surface. 
They serially conjugated paramagnetic nanoparticles to protein A-biotin and B7.1 
binding CTLA 4-immunoglobulin. The modified lentiviral particles were then 
captured by the modified-nanoparticles. The authors showed enhanced 
transduction of primary and established leukemia cells with this system.  
In addition to their utility as helper molecules for enhanced infection or vector 
purification, nanoparticles were tested for cellular labeling, drug delivery, imaging, 
hyperthermia, and as hybrid vectors for cell / vector separation and not to mention 
transfection [156,157]. Okon et al.[158] analyzed the biodegradation of iron-
dextran nanoparticles in rat, and suggested that nanoparticles appear as good 
targeting tools for both in vitro and in vivo biomedical applications. Recently 
nanoparticles were used for anti-cancer therapy. Here, nanoparticles were injected 
transperineally into the prostate [159]. Using alternating magnetic field applicator 
the nanoparticles were used to obtain hyperthermic to thermoablative 
temperatures that either render the prostate cancer cells sensitive to apoptosis or 
lead to direct cell killing, respectively. Kohler et al. [160] used iron nanoparticles to 
target the chemotherapeutic drug methotrexate (MTX) to cancer cells. The authors 
have modified the surface of nanoparticles with folic acid. Folic acid receptors are 
found at high densities on cancer cells. With this system they could show receptor-
mediated endocytosis of the particle/drug complex and release of MTX in the cell. 
The therapeutic effect was strictly cancer cell-specific. 
2.4. Gene therapy targeting prostate cancer and Prostate Stem Cell 
Antigen (PSCA) 
Prostate cancer (PCa) is among the most commonly diagnosed cancers in men in 
USA, and is estimated to be the second leading cause of male deaths in 2006 
[161]. Radical prostatectomy, radiation and androgen ablation therapies are the 
current treatment options for the advanced prostate cancer. However, following 
regression after the hormone depletion therapy some of the patients experience 
recurrence. Despite the advancements in detection methods and the therapy 
modalities, there is no effective treatment for patients with recurrent hormone-
resistant disease or patients who has metastatic disease at the time of diagnosis. 
Therefore, new therapy options are urgently needed.  
The prostate gland is a readily accessible organ, which allows easy application of 
the gene therapy vectors. In case of a suicide gene therapy, the by-stander effect, 
which is the diffusion of toxic products from the target cell to the neighboring cells 
mainly through gap junctions, is not very detrimental since prostate is an 
accessory organ. All these features make prostate cancer a suitable candidate for 
the gene therapy [162].  
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Several prostate specific proteins were analyzed for their suitability as anti-cancer 
targets. In analyses of mRNA and protein levels regarding the specificity and 
expression density, the “Prostate Stem Cell Antigen” (PSCA)- appeared as an 
appealing candidate for targeted immunotherapy against prostate cancer [163-
169]. PSCA is a 123 amino acid GPI-anchored protein. It shares 30% homology 
with the Stem Cell Antigen-2, from which the name is deduced [168]. Although the 
function of PSCA in the prostate tissue and its role in prostate carcinogenesis is 
yet unknown, the elevated protein expression level in prostate cancer and prostate 
metastasis to bone, in pancreatic cancer and human transitional cell carcinoma 
indicates its potential as target antigen [163,164,166,167,170]. In addition, Saffran 
et al. [171] pointed out to an anti-tumor effect of an anti-PSCA antibody where they 
demonstrated tumor regression of the human prostate cancer xenografts in mice. 
The same anti-PSCA antibody was also shown to inhibit prostate tumor growth in 
vivo by a Fc-independent mechanism [172]. Taken together, the current 
knowledge suggests PSCA as a good candidate for antibody-based anti-tumor 
therapy for advanced prostate cancer. 
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2.5. Aim 
The aim of this project was to generate ligand-modified VSV-G proteins for 
targeted anti-tumor therapy using retroviral vectors. Two strategies were employed 
for the targeted therapy: Direct recruiting of the viral particles onto the tumor cells 
(Figure 5) and bringing the viral vector in the vicinity of the target tumor cells via 
nanoparticles (Figure 6). In the first strategy the VSV-G protein was modified by a 
N-terminal insertion of a single-chain antibody fragment against the target tumor-
associated antigen, the PSCA. The scFv fragment allows the direct connection of 
the modified retroviral particle and the tumor cell. In the second approach, the 
VSV-G protein was modified by insertion of a small peptide. The linker molecules 
between the vector and the tumor cell were superparamagnetic nanoparticles, 
which are coupled to anti-PSCA and anti-myc antibodies. Both approaches should 
be followed in the same way, where functional properties of the modified envelope 
proteins such as intracellular transport, fusion and virus assembly should be 
assessed in a step-wise manner. 
 
Single-chain antibody fragment (A) against the tumor-associated antigen PSCA (B) is fused to the 
N-terminus of the VSV-G protein. The modified VSV-G proteins are used to pseudotype retroviral 
particles (C), which can then selectively bind to the PSCA on tumor cells whereby normal cells 
lacking the target molecule are spared. (D) 
Figure 5. Targeting strategy using scFv-modified viral particles. 
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A: Retroviral envelope proteins can be modified by insertion of a ligand or an epitope. B: Linker 
molecules (e.g. bispecific diabodies or nanobeads) can be generated, which are able to bind to the 
ligand-modified viral particle and a target molecule on the tumor cell simultaneously. C: Ligand-
modified viral particles can be directed specifically to the tumor cell that expresses the target 
molecules whereby normal cells lacking the target molecule are spared. 
Figure 6. Targeting strategy using ligand-modified viral particles and the nanobeads. 
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3. MATERIALS 
3.1. Chemicals 
The chemicals were purchased from Sigma (Taufkirchen, Germany), Merck AG 
(Darmstadt, Germany), Gerbu (Gaiberg, Germany) or Roth (Karlsruhe, Germany). 
Chemicals from other suppliers were stated when necessary. 
3.2. Primers  
All primers were purchased from MWG-Biotech AG (Munich, Germany). 
3.3. anti-PSCA/ anti-myc superparamagnetic nanobeads 
Superparamagnetic nanobeads coupled to anti-PSCA antibody (7F5, Dr. 
Agnieszka Morgenroth, Institute of Immunology) and anti-myc antibody 
(Invitrogen) were provided by Chemicell GmbH (Berlin, Germany). 
3.4. Enzymes 
 
3.5. DNA and Protein Markers 
GeneRuler 100bp DNA ladder Fermentas 
GeneRuler 1kb DNA ladder Fermentas 
PageRuler prestained protein marker Fermentas  
Precision Plus Dual Color prestained protein ladder BioRad  
R o c h eR N a s e A
A m e r s h a m  
B io s c ie n c e s
R e s t r ic t io n  e n d o n u c le a s e s
S ig m aT ry p s in / E D T A
P ro m e g aT 4  D N A  L ig a s e
S t ra t a g e n eH e r c u la s e h ig h  f id e l i t y  D N A  p o ly m e r a s e
S t ra t a g e n eE a s y - A  H ig h  F id e l it y  P C R  C lo n in g  E n z y m e  
M B I F e r m e n ta sD N a s e I
S u p p lie rE n z y m e
Table 1. Enzymes and their suppliers. 
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3.6. Solutions and Buffers 
Anode buffer I 300mM Tris-Base 
 20% Methanol (v/v) 
Anode buffer II 25mM Tris-Base 
 20% Methanol (v/v) 
Cathode buffer 25mM Tris-Base 
 40mM 6-Amino capronic acid (Fluka) 
6x Gel loading buffer 30% Gylcerin (v/v) 
 0.25% Bromophenolblue (w/v) 
 0.25% Xylenxyanol FF (w/v) (Fluka) 
Lysis Buffer 50mM Tris-HCl (pH 8.0) 
 300mM NaCl 
 2mM EDTA 
 1% NP-40 
 Protease inhibitor tablet (1 tablet/ 10ml buffer; Roche) 
Lysozyme 10mlg/ml chicken egg-white lysozyme in  
 10mM Tris-HCl, pH 8.0 
PBS 9.55g/l PBS Dry substance (Biochrome, Berlin) 
PFA 4%; 4g/100ml PBS 
Poly(ethylene)imine 
(PEI) 
50% (w/v ; Sigma-Aldrich) 
5x SDS sample buffer 50% Glycerin 
 15% SDS (w/v) 
 15% 2-Mercaptoethanol (v/v) 
 0.15% Bromophenolblue (w/v) 
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Sodium butyrate 500mM sodium butyrate 
 dissolved in 1x PBS and sterile filtered through 0.45µm 
filter 
STET buffer 10mM Tris-HCl, pH 8.0 
 1mM EDTA 
 0.1M NaCl 
 5% Triton X-100 (v/v) 
Stripping buffer 100mM 2-Mercaptoethanol  
 2% SDS 
 62.5mM Tris-HCl, pH 6.2 
TBE buffer 89mM Tris-HCl, pH 8.0 
 89mM Boric acid 
 2mM EDTA 
TBS 10mM Tris-HCl, pH 7.5 
 100mM NaCl 
TBS-TT TBS 
 0.2% Triton X-100 (v/v) 
 0.05% Tween 20 (v/v; Serva) 
TE buffer 10mM Tris-HCl, pH 7.5 
 1mM EDTA 
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StratageneF´{lacIq, Tn10(TetR)} mcrA (mrr-hsdRMS-mcrBC)  
80lacZ M15  lacX74 recA1 araD139  (ara-
leu)7697 galU galK rpsL (StrR) endA1 nupG
E.Coli TOP 10F´
StratagenerecA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 
lac [F´ proAB lacIqZ∆M15 Tn10 (Tetr)]
Epicurian Coli® XL-1 
Blue Competent 
bacteria
ProviderGenotypeBacteria
100µg/ml Penicillin/Streptomycin
10% FCS (v/v) (heat-inactivated)
D-MEM high glucose (4500mg/ml; Invitrogen)D-MEM complete
15g/l Agarose (Becton Dickinson)
LB mediumLB Agar
pH 7.0
1% NaCl (w/v) 
0.5% Yeast extract (w/v) (Becton Dickinson)
1% Trypton (w/v) (Becton Dickinson)LB medium
3.7. Bacteria 
E.coli TOP 10 F' (Stratagene, Amsterdam, Netherlands) bacteria were used for 
plasmid transformation experiments. For the Site-Directed Mutagenesis 
transformation experiments, Epicurian Coli® XL-1 Blue Competent bacteria, which 
were supplied with the ExSite PCR-Based Site-Directed Mutagenesis Kit 
(Stratagene) were used. Table 2 summarizes the genotypes of the bacteria used. 
 
3.8. Culture Media 
 
 
Table 2. Bacteria strains and their genotypic features. 
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3.9. Antibodies 
 
 
IB: Immunoblotting. IF: Immunofluorescence.
Sigma1:5000Anti-VSV-G-Cy3 conjugate
Provided by Prof. Douglas S Lyles 
(West Forest University, USA)
1:500Anti-VSV-G neutralizing (8G5, 
mouse)
Provided by Prof. Jean Grünberg
(University of Geneva, Switzerland)
1:400Anti-VSV-G 17-2-21-4 (mouse)
Sigma
1:2000 (IB)
1:5000 (IF)
Anti-VSV-G (P5D4, mouse)
Provided by Julian Bess (SAIC 
Frederick, NCI, USA)
1:250 (IB)
1:100 (IF)
Anti-p30 serum (goat)
Dianova1:50
Anti-mouse IgG (Fab’)2 –Cy3 
conjugate (goat)
Dako1:1000
Anti-mouse Ig HRP conjugate 
(rabiit)
Provided by Prof. Michael 
Bachmann (Institute of Immunology, 
Dresden)
UndilutedAnti-La 4B6 (mouse)
Dako1:2000
Anti-goat IgG HRP-conjugate 
(rabbit)
Upstate1:500
Anti-c-myc Alexa 488 conjugate 
(mouse)
Jackson Immuno Research Labs1:100
Anti- mouse IgG (H+L)-FITC 
conjugate (sheep)
Jackson Immuno Research Labs1:100
Anti- goat IgG (H+L)-Cy3 
conjugate (donkey)
SupplierDilutionAntibody
Table 3. Antibodies and the dilutions used. 
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In v itro g e nS u p e r  S c rip t  F irs t-S tra n d  S yn th e s is  S y s te m  fo r R T -P C R
Q ia g e nR N e a s y M in i K it  
In v itro g e nP C R  2 .1  T A  c lo n in g  k it
M il te n y i B io te cµ M A C S  c -m y c is o la t io n  k it
In v ite kIn v is o rb S p in  D N A  E x tra c t io n  K it
In v ite kIn v is o rb M a x i K it
E p ic e n treF a s t  L in k  D N A  L ig a tio n  K it
A m e rs h a m  B io s c ie n ce sE C L  P lu s  W e s te rn  B lo t  D e te c tio n  K it
S u p p lie rK it  s y s te m
3.10. Kit Systems 
 
3.11. Cell Lines 
The cell lines HEK 293, HEK 293T, HT1376, and RT4 were purchased from 
American Type Culture Collection (ATCC; Manassas, VA, USA) and were cultured 
as recommended by the supplier (Table 5). The PSCA-positive HEK 293-PSCA 
cell line was generated in the Institute of Immunology. HEK 293 cells were 
transfected with a plasmid encoding a glycosylphosphatidylinositol-anchored (GPI) 
PSCA and Geneticin resistance gene. The cell line was cultured under antibiotic 
selection. 
 
 
Adherent, epithelialHuman bladder carcinomaATCC; CRL-1472HT1376
Adherent, epithelialHuman bladder, transitional cell papillomaATCC; HTB-2RT4
Adherent, epithelialDerivative of HEK293ATCC; HEK 293T
Adherent, epithelialHuman embryonic kidney cellsATCC; CRL-1573HEK293
FeaturesOriginSupplierCell line
Table 4. Kit systems and the suppliers. 
Table 5. Cell lines and their basic features. 
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3.12. Plasmids 
pcz-VSV-Gwt encoding the VSV-G protein was kindly provided by Dr. Lindemann 
(Institute of Virology, Dresden). pMD.G2 plasmid coding for VSV-G protein was a 
gift from Prof. Trono (University of Geneva). The plasmid 
pRevCMV_PSCA_IRES2_EGFP encoding a GPI-anchored PSCA and EGFP 
separated by an IRES was generated at the Institute of Immunology.  
3.13. Other materials 
Sterile 0.45µm filters were purchased from Schleicher & Schuell (FP 30/0,45 CA-
S).
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4. MOLECULAR BIOLOGICAL METHODS 
4.1. Polymerase chain reaction 
Polymerase chain reaction (PCR) allows the amplification of DNA using a pair of 
oligonucleotides complementary to the 5' and 3' ends of the target DNA sequence. 
Basic components of DNA amplification by PCR are; a template DNA, DNA 
polymerase, oligonucleotide primers, dNTP and an appropriate buffer. For the 
amplification of the DNA sequence, the template DNA is first denatured where the 
hydrogen bonds connecting the DNA strands are broken at high temperature 
(95°C). Then the temperature is lowered to favor annealing of the oligonucleotide 
primers to their complementary sequences on the single-stranded DNA (ssDNA; 
generally around 50-60°C). In the next step – the elongation step-, the 
thermostable polymerase synthesizes the DNA sequence between the 
oligonucleotide primers (72°C). This reaction is repeated generally 25-30 times to 
achieve large amounts of target DNA sequence. In the last cycle, elongation step 
is typically extended up to 15 min to ensure complete synthesis of all available 
fragments. By PCR, it is possible to introduce mutations in the target sequence, as 
well as to modify ends of a DNA sequence for the ease of cloning into an 
appropriate vector. In Table 6 PCR conditions and primers used in this thesis are 
depicted. 
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TTT TTT CTA GAT TAC TTT 
CCA AG
VSV-G XbaI 
reverse
pAMI-G and 
pAMI-L-G
94oC → 2min
94oC → 30sec 
54 oC → 30sec
68oC → 105 sec    35 cycles
72oC → 1.5min
72oC → 7min
TTT TTT CTA GAA CTG GAA 
AAATG
VSV-G XbaI 
forward
TTTTTTCTAGATTACTTTCCAA
G
VSV-G-XbaI
reverse
pAMI-L-sG-1
95oC → 2min
95oC → 30sec 
68oC  → 30sec      35 cycles
72oC → 1.5min
72oC → 7min
TTTTCTAGATCTGAGCTTGCA
CTTGAGCTTTCCATGGACATC
ACCTTCTTCTCA
VSV-G-linker 
fuso3 forward
TTTTTTCTAGATTACTTTCCAA
G
VSV-G-XbaI
reverse
pAMI-L-sG-1
95oC → 2min
95oC → 30sec 
68oC → 30sec    35 cycles
72oC → 1.5min
72oC → 7min
TTTTCTAGATCTGAGCTTGCA
CTTGAGCTTCACCATGTGCTG
GTTGATGAATAC
VSV-G-linker 
fuso2 forward
AA AAA CTC GAG GCC TCC 
GCT GCC GCC GGC GCT ATT 
CAG ATC CTC
AMI linker 
reverse
pAMI-L-G
95oC → 2min
95oC → 30sec 
60oC → 30sec     34 cycles
72oC → 2.5min
72oC → 5min
TTTTTCTCGAGCCATGGAGAC
AGACACACT
AMI forward
AAAAACTCGAGGGCACTATTC
AGAT
AMI reverse
pAMI-G
95oC →2min
95oC → 30sec 
60oC → 30sec      34 cycles
72oC → 2.5min
72oC → 5min
TTTTTCTCGAGCCATGGAGAC
AGACACACT
AMI forward
Used in 
generation 
of
PCR conditions5'→ 3' sequencePrimer name
 
4.1.1. Ex-Site PCR-based Site-directed mutagenesis 
The Site-Directed Mutagenesis is a molecular biological technique to insert a 
desired mutation into a DNA sequence. Oligonucleotide primers containing that 
particular mutation are designed and the mutations are incorporated into the 
template by PCR. Myc epitope inserted-VSV-G protein-encoding DNA sequences 
were generated by ExSite PCR-Based Site-Directed Mutagenesis (Figure 7). Main 
components of this procedure were the mutagenesis buffer, two oligonucleotide 
primers -one of which was phosphorylated-, dNTP mix, a DNA polymerase blend 
and a template plasmid DNA. The components were mixed and the plasmid DNA 
was amplified by PCR using the primers and the conditions listed in Table 7. 
Subsequently, DpnI restriction enzyme was used to digest the parental double-
Table 6. PCR primers and PCR conditions. 
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stranded DNA (dsDNA) and the hybrid dsDNA, which consists of one parental and 
one mutated strand. DpnI recognizes the sequence 5'-Gm6ATC- 3' and digests the 
DNA fragments containing methylated adenine. Cloned Pfu DNA polymerase was 
then used to remove the 3' overhangs of the mutated DNA. Mutated DNA was 
intramolecularly ligated for 1hr at 37°C with T4 DNA ligase and the ligated DNA 
was used to transform Epicurian Coli XL-1 Blue supercompetent bacteria. 
 
ExSite PCR-based Site-Directed Mutagenesis is performed in four steps. In step 1, the template 
DNA is amplified with oligonucleotide primers containing the desired mutation. DpnI restriction 
enzyme digests the parental plasmids at the sequence 5´-Gm6ATC-3´ and Pfu DNA polymerase 
removes the 3’ overhang from the mutated DNA (Step 2). The modified DNA is intramolecularly 
ligated in Step 3 by T4 DNA ligase. The ligated DNA is then transformed into XL1-Blue 
supercompetent cells (Step 4). 
Figure 7. ExSite™ PCR-based Site-Directed Mutagenesis (www.stratagene.com ). 
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TGGAGCAGAGATACTTGACCCVSV-G myc 278 reverse
95°C → 45 sec
95°C → 45 sec
54°C → 45 sec            24 cycles
72°C → 7 min
72°C → 10 min
GAACAAAAACTCATCTCAGAAGAGGA
TCTGCAGTCTCAGACCTCAGTGGATGT
AAGT
VSV-G myc 278 forward
GAATCTGGCTGCAGCAAAGVSV-G myc 266 reverse
95°C → 45 sec
95°C → 45 sec
54°C → 45 sec            24 cycles
72°C → 7 min
72°C → 10 min
GAACAAAAACTCATCTCAGAAGAGGA
TCTGCAGCCTGAATGCCCAGAAGGGTC
AAGT
VSV-G myc 266 forward
GTCCTCTGAGAAGGTGVSV-G myc 208 reverse
94°C → 4 min
50°C → 2 min
68°C → 7.5 min
94°C → 1 min
54°C → 2 min              18 cycles
68°C → 7.5 min
68°C → 15 min
GAACAAAAACTCATCTCAGAAGAGGA
TCTGCAGGGAGAGCTATCATCCCTGGG
AAAG
VSV-G myc 208 forward
TCCTTTTTGGTTGTGTGGVSV-G myc 28 reverse
94°C → 4 min
50°C → 2 min
68°C → 7.5 min
94°C → 1 min
54°C → 2 min              18 cycles
68°C → 7.5 min
68°C → 15 min
GAACAAAAACTCATCTCAGAAGAGGA
TCTGCAGAACTGGAAAAATGTTCCTTCT
AATT
VSV-G myc 28 forward
CTTGCAATTCACCCCAATGVSV-G myc 17 reverse
94°C → 4 min
50°C → 2 min
68°C → 7.5 min
94°C → 1 min
54°C → 2 min              18 cycles
68°C → 7.5 min
68°C → 15 min
GAACAAAAACTCATCTCAGAAGAGGA
TCTGCAGTTCACCATAGTTTTTCCACAC
AAC
VSV-G myc 17 forward
PCR conditions5’→3’ sequencePrimer designation
  
4.1.2. Generation of La epitope-modified VSV-G proteins 
La epitope was inserted into VSV-G coding sequence in pMD.G2 by PCR 
amplification. Briefly, for each construct La sequence was inserted into VSV-G 
coding sequence by PCR amplification of N- and C-terminal flanking regions using 
the conditions and the primers depicted in Table 8. The primer pairs were 
designed to insert the La epitope and restriction enzyme sites for the cloning. PCR 
products were first cloned into pGemT vector separately and brought together in 
pGemT using XhoI restriction site. The La epitope-modified VSV-G sequence was 
then cut out from pGemT using the internal restriction sites (Hind III and AgeI) into 
pMD.G2 vector, which was also digested with the same enzyme combination. 
Table 7. Primers for ExSite PCR-based Site-directed Mutagenesis 
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GGAGCAGCAATATCGACTVSV-G 4R
95°C 5min
95°C 30 sec
53°C 45sec          30 cycles
68°C 45 sec
68°C 5min
CTCGAGAAAGAAGCACTGAAGAAAATA
ATAGAAGACCAACAAGAATCCCTAAACA
AAGAAGGGTCAAGTATCTCT
VSV-G 4B6 XVIII 9F
VSV G La 275 C terminus
CTCGAGTGGGCATTCAGGGAATCTVSV-G (XhoI) 10R
95°C 5min
95°C 30 sec
56°C 45sec          30 cycles
68°C 1min 45sec
68°C 5min
GACCTCCATAGAAGACACCVSV-G 5F
VSV G La 27 N terminus
GGAGCAGCAATATCGACTVSV-G 4R
95°C 5min
95°C 30 sec
53°C 45sec          30 cycles
68°C 45 sec
68°C 5min
CTCGAGAAAGAAGCACTGAAGAAAATA
ATAGAAGACCAACAAGAATCCCTAAACA
AAGGAGAGCTATCATCCCTGGG
VSV-G 4B6 XVIII 7F
VSV G La 209 C terminus
CTCGAGGTCCTCTGAGAAGAAGGTVSV-G (XhoI) 6R
95°C 5min
95°C 30 sec
53°C 45sec          30 cycles
68°C 1min 45sec
68°C 5min
GACCTCCATAGAAGACACCVSV-G 5F
VSV G La 209 N terminus
GGAGCAGCAATATCGACTVSV-G 4R
95°C 5min
95°C 30 sec
52°C 45sec          30 cycles
68°C 1min 45sec
68°C 5min
CTCGAGAAAGAAGCACTGAAGAAAATA
ATAGAAGACCAACAAGAATCCCTAAACA
AACCTTCTAATTACCATTATTGC
VSV-G 4B6 XVIII 3F
VSV G La 31 C terminus
CTCGAGAACATTTTTCCAGTTTCCVSV-G (XhoI) 2R
95°C 5min
95°C 30 sec
50°C 45sec          30 cycles
68°C 45sec
68°C 5min
GACCTCCATAGAAGACACCVSV-G 5F
VSV G La 31 N terminus
GGAGCAGCAATATCGACTVSV-G 4R
95°C 5min
95°C 30 sec
53°C 45sec          30 cycles
68°C 1min
68°C 5min
CTCGAGAAAGAAGCACTGAAGAAAATA
ATAGAAGACCAACAAGAATCCCTAAACA
AATTCACCATAGTTTTTCCAC
VSV-G 4B6 XVIII 11F
VSV G La 17 C terminus
CTCGAGCTTGCAATTCACCCCAATGVSV-G 4B6 XVIII 12R
95°C 5min
95°C 30 sec
57°C 45sec          30 cycles
68°C 1min
68°C 5min
GACCTCCATAGAAGACACCVSV-G 5F
VSV G La 17 N terminus
PCR conditions5’→3’ sequencePrimer designationLa-modified VSV G protein 
designation
 
 
La-epitope insertion mutants were generated by PCR amplification of VSV-G coding 
sequence from pMD.G2 plasmid. The La sequence is written bold and the restriction 
endonuclease recognition sites are written italic. 
4.2. Restriction endonuclease digestion of DNA fragments 
Restriction endonucleases are enzymes, which recognize specific DNA sequences 
and introduce double-stranded breaks in DNA. Depending on the sequence 
recognized by the restriction endonuclease and the type of strand break 
generated, the DNA fragments may have either “sticky” or “blunt” ends. The sticky-
end DNA fragments have overhanging nucleotide sequences, which can be ligated 
to another DNA fragment possessing a complementary overhang. On the other 
hand, the blunt-end DNA fragments have no overhangs and can therefore be 
ligated to any blunt-end DNA fragment regardless of the restriction endonuclease 
Table 8. Primers for PCR-based insertion of La epitope in VSV-G ectodomain. 
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used to generate these fragments. For analytical and preparative purposes 
restriction endonucleases were used with recommended buffers and the restriction 
digestion was performed under optimum conditions for each enzyme, i.e. 
temperature, salt concentration, presence of bovine serum albumin, etc.  
4.3. Agarose electrophoresis of DNA fragments 
Agarose electrophoresis allows the separation of DNA fragments in an agarose 
matrix using electrical field. The negatively charged DNA fragments are forced to 
move along the electrical field. In general, smaller DNA fragments move faster 
than larger DNA fragments, but also the conformation of DNA has an impact, such 
that the supercoiled circular DNA fragments move faster than the linear DNA 
fragments, which in turn move faster than the open-circular DNA fragments. 
Adjusting the percentage of agarose, it is possible to determine the pore size of 
the agarose matrix. High agarose concentration slows down the overall speed of 
DNA molecules in the matrix and thus permits a better separation of smaller DNA 
fragments. Separated DNA fragments can be visualized with ethidium bromide 
(EtBr), a dye that intercalates with DNA and fluoresces under UV light.  
The agarose (Serva) concentration was adjusted to 0.8-1.5% (w/v) in 0.5xTBE 
buffer, depending on the length of the fragments to be separated. Agarose was 
dissolved in buffer by heating and 0.2µg/ml EtBr was added after the gel cooled 
down. The gel was prepared in a horizontal gel electrophoresis chamber 
(Amersham Biosciences) and the samples were loaded after mixing with 6x gel 
loading buffer at 1:5 ratio. For estimation of the DNA fragment length, DNA ladders 
were run on the same gel. The gel chamber was filled with 0.5x TBE buffer and 
samples were run under 7V/cm electrode distance. The bands were visualized by 
UV-transilluminator (Biostep; Jahnsdorf). 
4.3.1. Isolation of DNA fragments from agarose gel 
DNA fragments separated in an agarose gel can be extracted to isolate a specific 
band. The band corresponding to the target DNA fragments was cut out with a 
scalpel. The agarose matrix was melted at 50°C with “the gel solubilizing buffer” 
supplied in the Invisorb Spin DNA Extraction Kit and DNA fragment in agarose 
was bound onto a filter. The filter was washed to remove unbound impurities. 
Elution buffer was added and the purified DNA was eluted by centrifugation. DNA 
fragment was then used for cloning immediately or stored at -20°C. 
4.4. Cloning of DNA fragments 
PCR products or DNA fragments obtained by digestion with restriction 
endonucleases can be cloned into vectors for further use. The cloning is 
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accomplished by ligation of either two compatible sticky-end DNA fragments or 
two blunt-end DNA fragments with DNA ligases in the presence of an appropriate 
buffer. In this study, ligations were performed with the Fast Link DNA Ligation Kit, 
unless otherwise stated. The insert DNA fragment and the vector DNA were 
digested with restriction endonucleases. The fragments were then separated from 
impurities by agarose gel electrophoresis and bands at correct sizes were isolated. 
Isolated insert and vector DNA were mixed at a 3:1 (Insert: Vector) ratio in the 
presence of recombinant ATP and the ligation buffer, and the mixture was 
incubated 5 min for sticky-end ligations or 15 min for blunt-end ligations at room 
temperature (RT). Then the ligase activity was ceased by incubation at 70°C for 
15min. An aliquot (~2µl) of the ligation mixture was used to transform bacteria, and 
the rest was stored at -20°C. 
4.4.1. Cloning of glycosylphosphatidylinositol (GPI)-anchored PSCA  
A glycosylphosphatidylinositol anchored PSCA encoding pPSCA-IRES2-EGFP 
plasmid was first digested with HpaI. After inactivating HpaI, SmaI was added. The 
linearized plasmid was run on the gel and the DNA fragment containing PSCA was 
isolated. The gel-purified DNA fragment was then re-ligated using T4 DNA ligase 
and the plasmid was named pPSCA-IRES. The plasmid contains only a part of the 
IRES sequence.  
4.4.2. Cloning of scFv anti-PSCA / VSV-G fusion protein 
The single-chain antibody variable fragment against the tumor-associated antigen 
PSCA (AMI) was amplified from pSecTag 2B-AMI plasmid by PCR using AMI-
forward and –reverse primers (Table 6). Primers were selected such that the Ig Κ 
leader sequence from pSecTag2B, which directs the downstream protein for 
secretion, was also amplified. Shortly, anti-PSCA scFv and VSV-G encoding DNA 
sequences were amplified separately with PCR and were cloned into PCR vectors 
(pCRII or pCR3.1, respectively) using the TA Cloning Kit (Invitrogen). Restriction 
enzyme recognition sites were included in the PCR primers (Table 6) both to 5’ 
and 3’ ends of the sequences to facilitate further cloning. AM-I was amplified with 
primers coding for XhoI restriction site with or without linker, whereas the VSV-G 
amplification primers contained XbaI recognition site. First, AM-I coding sequence 
from pCRII vector was cloned into pcDNA3.1 following digestion of both plasmids 
with XhoI, which linearized pcDNA 3.1 (pAMI or pAMI-L). Next, VSV-G sequence 
was cloned into pAMI or p-AMI-L vectors using XbaI restriction enzyme, which 
cuts off VSV-G sequence from pCR 3.1 vector and linearized pAMI or pAMI-L. The 
plasmids were designated pAMI-G or pAMI-L-G, respectively.  
VSV-G mediates binding of viral particles to the target cell surface via a 
ubiquitously expressed molecule [124]. Despite several evidence showing 
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particular sequences in VSV-G as being necessary for target binding, the exact 
sequence(s) responsible for the cellular target binding of VSV-G has not been yet 
identified. Therefore, VSV-G sequence contribution in the fusion protein was 
reduced to study whether it is possible to diminish wild-type VSV-G protein binding 
while enhancing specific targeting via AMI part of the fusion protein. pAMI-L was 
used as template for the fusion proteins with shortened VSV-G. The VSV-G 
sequence was amplified by PCR with primers, which encoded XbaI restriction site, 
an additional linker of 7 amino acids and generated 5’-end truncated VSV-G 
sequences. PCR products were cloned into pCR 2.1 vector using TA cloning kit. 
XbaI restriction sites were used to clone truncated VSV-G into linearized pAMI-L 
vector to generate pAMI-L-sG-1 and pAMI-L-sG-2. 
4.5. Transformation of competent E.coli according to Hanahan [173] 
Chemically competent E.coli bacteria were thawed on ice. 50µl of competent 
bacteria were mixed with 1µg of DNA and incubated 30 min on ice. Following the 
subsequent heat-shock for 2 min at 42°C in water-bath, 950 µl warm LB medium 
without antibiotics was added and the bacteria were grown 1hr at 37°C shaker. 
The 100 µl and 900 µl aliquots of bacteria were plated on LB-agar plates with 
antibiotic and incubated overnight at 37°C. 
4.6. Plasmid mini preparation according to Holmes and Quigley [174] 
Single-bacteria colonies were picked with a sterile tip and grown overnight 
(~18hrs) in 5 ml LB medium with antibiotic at 37°C shaker. Next day, 1.5ml of 
bacteria suspension was centrifuged to pellet down the bacteria and DNA was 
isolated according to protocol from Holmes & Quigley [174]. Briefly, bacteria pellet 
was re-suspended in 350µl of STET buffer and 25µl lysozyme solution was added. 
Suspension was boiled for 40sec and centrifuged at 14000rpm for 10min. 
Subsequently the pellet was removed with a sterile toothpick and 40µl sodium-
acetate (2.5M, pH 5.2) and 420µl isopropanol were added to the supernatant. 
Following 5min incubation at RT the mixture was centrifuged. The supernatant 
was discarded and the pellet was washed with 250µl 70% ethanol. After removal 
of ethanol by centrifugation, DNA was re-suspended in 50µl H2O and 2µl RNase A 
was added. 
4.7. Plasmid maxi preparation from E.coli 
For the amplification of plasmid DNA, 200µl of culture suspension from 
transformed E.coli was grown overnight in 100ml LB medium with antibiotics. Next 
day, the bacteria suspension was centrifuged and the plasmid DNA was isolated 
using the Invisorb Plasmid Maxi Preparation Kit according to manufacturer's 
instructions. Briefly, bacteria were pelleted and lyzed under alkaline conditions. 
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50CAAGATCCTCTCAACGTCG-position 868 reverse
56CATTGGGGTGAATTGCAAGVSV G-SG forward
56TAATACGACTCACTATAGGGT7 promoter
56GGAAACAGCTATGACCATGM13 reverse
54TGTAAAACGAACGGCCAGTM13 Universal (-21)
56TAGAAGGCACAGTCGAGGBGH reverse
Tm (oC)5‘→3‘ sequencePrimer designation
The crude bacteria lysate was cleared by centrifugation and DNA was bound onto 
a filter. Plasmid DNA free from impurities was eluted in a low-salt buffer. 
Concentration and purity of isolated DNA was measured by the optical density 
(OD) at 260nm and OD260/OD280 ratio, respectively (BioPhotometer, Eppendorf, 
Hamburg; using Eppendorf plastic cuvettes). 
4.8. Sequencing of nucleic acids 
DNA sequences were verified at the DNA Sequencing Facility of Max Planck 
Institute for Cell Biology and Genetic (MPI-CBG, Dresden) using insert- or vector-
specific primers. The sequencing primers are listed in Table 9. 
 
4.9. Discontinuous Sodium Dodecyl Sulfate - Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
SDS-PAGE allows the separation of proteins according to their molecular weights. 
Protein samples were prepared in a reducing sample buffer. The reducing sample 
buffer contains anionic detergent SDS, which denatures the secondary and non-
disulfide-bond depended structures in the protein, and 2-Mercapthoethanol, which 
reduces disulfide-bonds. In addition to its denaturing effect on protein, SDS 
assigns a negative charge to the protein in correlation with its mass. Due to this 
uniform mass: charge ratio proteins are separated mainly according to their sizes. 
With the help of a predefined protein molecular marker, it is possible to estimate 
the molecular weight of a sample. For SDS-PAGE Tris-HCl/Tris-Glycine buffer 
system was used. Acrylamid/N,N'-Methylenbisacrylamide (1:19, 40% stock 
Table 9. Sequencing primers and annealing temperatures. 
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A B
solution; Gerbu) concentration was adjusted depending on the experiment and 
varied between 8-12%. The protein samples were mixed with 5x SDS Sample 
buffer and were boiled at 95°C for 5-10 min before loading on the gels. BioRad 
Protean-3 chambers were used. The electrophoresis was performed at 60V for the 
collecting gel and 120V for the separating gel (BioRad Power Pac 3000). Precision 
Plus Dual Color (BioRad) or PageRuler (Fermentas) protein marker was used as 
the standard (Figure 8). 
 
A: Precision Plus Dual Color protein marker (BioRad) with 70kDa and 25kDa as reference bands. 
B: Fermentas PageRuler protein marker with 70kDa and 27kDa as reference bands. 
4.10. Western blot analysis 
Following the SDS-PAGE separation of proteins in a sample, the proteins were 
transferred onto a Polyvinylidenfluorid (PVDF) membrane for immunoblotting. SDS 
gel containing the separated proteins was placed face-to-face with a PVDF-
membrane in a “sandwich model”. In sandwich-model, from bottom to up 4 sheets 
of filter paper incubated in anode buffer-I, 4 sheets of filter paper incubated in 
anode buffer-II, PVDF-Membrane equilibrated in methanol and anode buffer-II, 
gel, and 8 sheets of filter paper incubated in cathode buffer were placed in a 
BioRad Trans-Blot SD Semi-Dry transfer apparatus. Under 25V current, proteins 
were transferred for 2 hours onto the membrane while preserving their 
organization in the gel. Non-specific reaction of antibodies was prevented by 
blocking the membrane overnight under agitation with 3% Bovine Serum Albumin 
(BSA) in Tris-buffered saline (TBS). Next day, the membrane was washed 
thoroughly with TBS under agitation before being incubated with the primary 
antibody against the protein of interest. The unbound antibody was removed by 
Figure 8. Protein molecular weight markers. 
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successive washing and the membrane was then incubated with a horseradish 
peroxidase-labeled secondary antibody against the species in which the primary 
antibody was raised. Detection of the protein on the membrane was performed by 
enhanced chemiluminescence (ECL) reaction, where horseradish peroxidase acts 
as a catalyzer. Visualization was performed either with a light-sensitive Hyperfilm 
(Amersham) or with Fuji LAS 3000. 
4.10.1. Detection of VSV-G protein 
Total cell lysates were prepared by harvesting the cells in a lysis buffer. The VSV-
G was detected by incubating the membrane with a mouse anti-VSV-G antibody 
(P5D4, 1:2000 diluted in 3%BSA-TBS) for 2hours at RT. The membrane was then 
washed with TBS-Tween 20-Triton X-100 (TBS-TT) and TBS. As secondary 
antibody rabbit anti-mouse Ig-HRP conjugate (DAKO) was used (diluted 1:1000 
with 3%BSA-TBS). Following 1hour incubation at RT with the secondary antibody, 
the antibody-reactive bands were detected. 
4.10.2. Detection of MLV capsid protein p30 
Viral particles produced by the packaging cells contain the viral envelope protein 
and the capsid protein. The co-presence of MLV capsid protein p30 in the same 
blot was used to demonstrate that the whole viral particles were detected, and not 
only the viral envelope protein shed by the packaging cells. The membrane 
containing the purified viral supernatants, which was first used to detect VSV-G, 
was stripped under stringent conditions. The membrane was washed with TBS-TT 
and TBS, and was blocked overnight with 3%BSA-TBS. Next day, the membrane 
was washed and incubated 2 hours at RT with goat anti-MLV p30 serum (1:250 
diluted in 3%BSA-TBS; NCI, USA). Following intensive washing with TBSTT and 
TBS, the membrane was incubated with rabbit anti-goat IG-HRP antibody (DAKO, 
1:1000 in 3%BSA-TBS) for 1 hour at RT. The bands were detected with ECL 
reaction and using the Hyperfilm or with Fuji LAS 3000. 
4.10.3. Binding of anti-PSCA/ anti-myc nanobeads to myc-modified 
virus  
The myc epitope-modified VSV-G proteins were used to pseudotype retroviral 
particles. The packaging cell supernatant containing the viral particles was mixed 
with anti-myc / anti-PSCA nanobeads in orbital shaker for 30min at 37°C. The 
mixture was then centrifuged at 14000 rpm at 4°C for 30min. The pellet was re-
suspended in SDS sample buffer and analyzed by SDS-PAGE and Western 
blotting. Anti-p30 serum and HRP conjugated rabbit anti-goat Ig was used to 
detect MLV capsid protein in the samples. The protein bands were visualized 
using ECL Plus kit and Fuji LAS 3000. 
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5. CELL BIOLOGICAL METHODS 
5.1. Cell count determination 
Cells were centrifuged and pelleted. The pellet was re-suspended in 1ml of culture 
medium, from which 10µl was taken out and mixed with 90µl of Trypan blue 
solution. Trypan blue dye is excluded from the membrane of viable cells, but not 
from that of dead cells. Thus the dead cells appear blue under the microscope. 
The viable cells were counted from 64 small squares of Neubauer chamber, and 
using the following formula the cell count was determined; (cell count / 4) x the 
dilution factor x 104.  
5.2. Freezing and thawing of cell lines 
Cells were pelleted by centrifugation and the pellet was re-suspended in 90% fetal 
calf serum (FCS)-10% Dimethylsulfoxyde (DMSO). Cell suspension was placed in 
a cryobox filled with 2-propanol, which ensures a cooling down process at 1°C/min 
rate. Then the cryobox was placed in -80°C refrigerator, for long-term storage cells 
were transferred into a liquid nitrogen tank. Frozen cells were thawed in a water-
bath at 37°C and were taken into FCS. The suspension was centrifuged and the 
DMSO-containing supernatant was removed completely. The pellet was re-
suspended in the respective culture medium. 
5.3. Cultivation of cell lines 
HEK 293T, HEK 239wt, and RT4 cell lines were cultured in high glucose DMEM. 
For cells transfected with an expression vector encoding for a selection marker, 
appropriate amount of the respective antibiotic was added to the culture medium. 
HEK 293-pPSCA cells, which were transfected with an expression vector 
conferring Geneticin resistance, were cultured in DMEM supplemented with G418 
at 0,5µg/ml concentration. HT1376 cell line was cultured in DMEM high glucose 
medium in the presence of 1% non-essential amino acid solution (Biochrom, 
100x). All media were supplemented with 10% FCS, 100µg/ml 
penicillin/streptomycin (Biochrom). 
5.4. Transfection of cell lines 
Transfections were performed using poly(ethylenimine) (PEI) solution (Sigma). PEI 
is a polycation, which binds to and precipitates DNA. Target cells were plated one 
day prior to the transfection. PEI was used (1mg/ml) to precipitate DNA in the 
culture medium for 20min at RT. The precipitate was used to transfect the cells 
overnight at 37°C or 32°C. Next day, the transfection medium was removed and 
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cells were incubated with culture medium containing sodium butyrate at a final 
concentration of 10mM for 8hours to induce Cytomegalovirus (CMV) promoter-
dependent protein expression. Transfected cells were then cultured in the optimal 
culture medium until further analysis. 
5.4.1. Generation of PSCA-positive HEK293 cell line 
HEK293 wt cells were transfected with plasmid encoding a GPI-anchored PSCA 
and Geneticin (G418) resistance gene (pPSCA-IRES). The transfected cells were 
cultured under antibiotic selection (0.5µg/ml) at 37°C. The cell line was designated 
HEK293-PSCA. In addition, HEK 293-PSCA-IRES-EGFP cells were generated by 
transient transfection of HEK293 cells with pRevCMV_PSCA_IRES2_EGFP -a 
retroviral vector encoding for GPI-anchored PSCA and EGFP (separated by an 
Internal Ribosome entry site).  
5.4.2. Viral particle preparation 
One day prior to the transfection 4x106 HEK293T cells were plated in 10cm dish. 
Next day, the virus packaging was performed as described by Soneoka et al. [3]. 
In this three-vector system, the packaging cells were co-transfected with retroviral 
vectors encoding gag-pol gene products (pHIT60), the gene of interest or the 
reporter gene (pcz-CFG2-fEGFPf) and the envelope protein (pcz-VSV-Gwt or 
myc-modified pcz-VSV.G ). Conditioned medium containing the viral particles was 
collected 48 hours after transfection and filtered through a 0.45µm filter. The 
supernatant was either used immediately or stored at -80°C. The packaging cells 
were fed with fresh medium for a second virus harvest on the 3rd day after the 
transfection. Following the second harvest total cell lysates were prepared from 
the packaging cells. 
5.5. Transduction of cell lines 
Moloney Murine Leukemia Virus-(MoMuLV)-based retroviral vectors were 
produced (see chapter 5.4.2). pcz-CFG-5.1-MCS was used as the template for 
retroviral vectors. This retroviral vector contained the packaging signal Ψ, which is 
required for the assembly of newly-synthesized retroviral RNA into viral particles. 
Ψ is flanked on the 5'- and 3'- ends with LTRs, which contain the promoter 
elements in the viral genome. Supernatants containing the viral particles were 
harvested from the packaging cells 48 and 72 hours after transfection and pooled. 
Target cells were incubated overnight with the pooled supernatant in the presence 
of 8µg/ml Polybrene (Hexadimethrinbromide), when not otherwise stated. Next 
day, the medium was replaced. 
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5.5.1. Determination of virus titer 
VSV-Gwt or modified VSV-G-pseudotyped EGFP-encoding viral particles were 
produced. The supernatants were harvested from the packaging cells and 
concentrated by 100fold (total volume 500µl) via ultracentrifugation. The 
concentrate was divided into 50µl aliquots and frozen at -80°C. On the same day 
target HEK293wt and HEK293-PSCA cells was plated at 2x104 cells/ well in 48-
well plates. The next day, one aliquot was thawed and titrated on the target cells 
by serial dilution (101 to 106) in a total volume of 1ml. Twenty-four hours later the 
medium was replenished and the cells were further cultivated. On day 2 after 
transduction, EGFP-positive colonies were counted and the titer (virus particle/ml) 
was calculated as follows: the number of EGFP-positive colonies x the dilution 
factor x 20.  
5.5.2. Transduction of HEK293wt cells with myc epitope-modified viral 
particles in the presence of anti-myc antibody 
HEK293T cells were plated in 24-well plates (5x104 cells / well) and grown 
overnight. Fresh supernatant from the packaging cells was used for transduction. 
Transduction was performed with 1ml supernatant (from 32°C packaging) and in 
the presence of one of the following antibodies at a final concentration of 1µg/ml: 
anti-Xpress, anti-c-myc or neutralizing anti-VSV-G antibody (8G5, a generous gift 
from Prof. Lyles, USA) and polybrene. Transduction was performed overnight, 
after which the medium was replenished. Transduction efficiencies were analyzed 
by flow cytometry 2 days after transduction. 
5.5.3. Transduction of PSCA-positive cells with myc-modified viral particles 
in the presence of anti-myc/anti-PSCA antibody-coupled nanobeads 
Viruses were produced at 37°C. The supernatant was harvested and filtered 
(0.45µm) and concentrated 100fold by ultracentrifugation. The viral particles were 
re-suspended in culture medium. VSV-G myc 17-pseudotyped retroviral particles 
(MLV(G-myc 17) )were incubated 3hrs at RT in orbital shaker with magnetic beads 
and the mixture was used for transduction. When indicated the virus-magnetic 
bead mixture was incubated 1hr on a magnet and thereafter the precipitate and 
the supernatant were used promptly to transduce PSCA-positive and PSCA-
negative cells, which were plated the previous day. VSV-G wt-pseudotyped 
retroviral particles were used without incubation with the nanobeads and in the 
presence of polybrene (8µg/ml). Next day the medium was replenished and the 
cells were further incubated at 37°C until the transduction efficiency was measured 
on 2 days post-transduction by FACS.  
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5.5.3.1. Confirmation of nanobeads internalization into PSCA-positive cells 
transduced with MLV(G-myc 17) particles 
MLV(G-wt) and MLV(G-myc 17) particles were used for transduction of PSCA-negative 
and PSCA-positive cells in the excess of nanobeads. The transduced cells were 
cultivated for a week, in which the cells were splitted and washed intensively with 
PBS. On the last day, the cells were centrifuges and re-suspended in PBS and 
dried on Whatman paper. The Whatman paper was then scanned for 
documentation. 
5.6. Preparation of cell lysates 
Medium was removed from the cells. Cells were washed 2 times with PBS each 
for 5min. PBS was removed and cells were harvested directly in lysis buffer. All 
procedure was performed on ice. The cell lysates were either used immediately or 
was stored at -20°C. 
5.7. Viral particle purification and concentration 
5.7.1. Concentration of viral particles via ultracentrifugation 
Viral particles were harvested from packaging cells at different time points and 
were pooled. Ultracentrifugation was performed with Beckman Coulter L60 
ultracentrifuge using SW40Ti or SW28 rotors. The samples were centrifuged at 
100 000 x g at 4°C for 2 hours. Then, the supernatant was discarded carefully, and 
the viral particles were re-suspended in culture medium. 
5.7.2. Purification of myc-modified viral particles with µMACS c-myc 
isolation kit 
Viral particles were produced with VSV-Gwt or c-myc-modified VSV-G envelope 
proteins. The particles were purified from medium from packaging cells via 
µMACS c-myc Isolation Kit (Miltenyi Biotec). Briefly, filtered (0.45µm) supernatant 
(~5ml) was mixed with 50µl of anti-myc magnetic beads. The mixture was 
incubated on ice for 30min under occasional mixing. During this incubation, µ 
column was equilibrated with 200µl lysis buffer and washed three times with PBS.  
At the same time, aliquots of elution buffer were placed in a pre-heated (95°C) 
thermo block. The mixture was then applied to the column and run through. The 
column was washed (2x 400µl wash buffer 1, 1x100µl wash buffer 2) and 
incubated 5min with 20µl pre-heated elution buffer. Samples were eluted in 50µl of 
pre-heated elution buffer and were analyzed by SDS-PAGE. 
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5.8. Immunofluorescence analysis 
Immunofluorescence analysis enables the detection proteins using antibodies 
recognizing specific epitopes on them. In the indirect immunofluorescence 
analyses unlabeled primary antibodies are used to localize the protein of interest. 
Then the detection is achieved by fluorescent dye-labeled secondary antibody. 
The secondary antibody is specific to the species from which the primary antibody 
was obtained. In the direct immunofluorescence analysis, the proteins are 
detected by a fluorescence dye-labeled primary antibody. 
5.8.1. Intracellular staining 
For the detection of intracellular VSV-G protein expression, HEK293T cells were 
transfected with respective expression vectors. Two days after transfection cells 
were permeabilized 5min at RT with 0.37% paraformaldehyde (PFA) and 0.05% 
Triton X-100 and fixed for 15min at RT with 3.7% PFA. Cells were then washed 2 
times with PBS each for 5 min and were incubated with Cy3 conjugated anti-VSV-
G antibody P5D4 (diluted 1:5000) for 1 hr at RT. For the capsid protein detection, 
the cells were fixed with 3,7% PFA and stained with a goat anti-p30 serum (1:100) 
and revealed by donkey anti-goat IgG (H+L)-Cy3 antibodies.  
5.8.2. Surface staining  
Proteins expressed on the cell surface can be detected under native conditions, 
which do not disrupt the cell membrane. To detect VSV-G protein on the surface of 
transfected cells, HEK293T cells were incubated with anti-VSV-G antibody (17-2-
21-4) (diluted 1:400), which recognizes an extracellular epitope, for 1 hr on ice. 
The cells were then washed with PBS and were incubated 1hr on ice (dark) with 
Cy3 conjugated goat anti-mouse Ig F(ab')2 antibody (GAM-Cy3, diluted 1:50). 
Samples were then fixed with 4% PFA for 10min on ice. Accessibility of the c-myc 
epitope on the modified VSV-G protein was assessed using Alexa 448-coupled 
anti-c-myc antibody (1:500) for 1 hr on ice in dark. The cells were then fixed with 
4%PFA for 10 min on ice. La epitope was on the transfected cells using anti-La 
antibody 4B6 (undiluted, 1 hr on ice) and Cy3 labeled goat anti-mouse Ig F (ab') 2 
antibody (GAM-Cy3, diluted 1:50). Cells were then fixed with 4%PFA. PSCA 
expression was detected on cells from Glioblastoma Multiforme (GBM) patients. 
Cells were stained for 1hour on ice with anti-PSCA antibody 7F5 and then 
secondary antibody sheep anti-mouse Cy3. Cells were then fixed for microscopy. 
DNA counter staining was performed when applicable with Hoechst 33342 dye 
(10mg/ml stock solution diluted 1:1000) prior to the staining. The stainings were 
observed with a Zeiss Meta 510 Confocal Laser Scanning Microscope.  
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5.8.3. Binding of anti-PSCA/anti-myc nanobeads onto PSCA-positive cells 
HEK293wt, HEK293-pPSCA, HT1376 and RT4 cells were plated at a density of 
104/ well in 8-well chamber slides. On the subsequent day, cells were incubated 
with anti-PSCA /anti-myc magnetic beads either at 37°C 240 min. Cells were then 
washed with PBS to remove unbound magnetic beads. The bound magnetic 
beads were detected with a goat anti-mouse IgG F(ab’)2 antibody coupled to Cy3. 
5.9. Confocal laser scanning microscopy 
The confocal laser scanning microscopy was performed with a Zeiss Meta 510 
Confocal Microscope (BIOZ, TU-Dresden). 
5.10. Membrane fusion assay 
VSV-G protein-mediated membrane fusion was demonstrated by a fusion assay. 
HEK 293T cells were co-transfected with VSV-Gwt or modified G protein 
expressing vector and an EGFP encoding expression vector in 24-well plates at 
32°C or 37°C. The cells were incubated at RT for 10min with PBS adjusted to a 
certain pH (pH range 5.0 to 7.5 at 0.5 unit intervals). Then, cells were incubated at 
respective temperature for 3hrs with culture medium, before the fusion induction 
was repeated. After 3 hrs incubation following second fusion induction, cells were 
fixed and were observed with a Zeiss Axiovert 200M microscope.  
5.11. Flow cytometry analysis 
Flow cytometry enables analysis of cells using the principles of light scattering, 
light excitation and fluorochrome emission. Fluorescently labeled cells are forced 
under high pressure to intercept a laser beam, where they scatter light and 
fluorochromes are excited to a higher energy level. From the scattered light, it is 
possible to gain information about the cell volume (Forward cell scatter; FSC) and 
the cellular complexity such as granularity (Side scatter; SSC). Transduced cells 
were analyzed by a Becton Dickinson Flow Cytometer, and the transduction 
efficiency was determined in terms of EGFP or DsRed fluorescence gating on the 
living cells. For confirmation of the PSCA expression on the HEK293-PSCA cells, 
cells were natively stained with a monoclonal affinity-purified anti-PSCA antibody 
and a goat anti-mouse Cy3 conjugated antibody. The positive cell amount was 
measured by FACS. 
5.12. Apoptosis analysis 
Anti-PSCA/ anti-myc antibody-coupled nanobeads were analyzed for the induction 
of apoptosis in PSCA-negative and PSCA-positive cells. The cells were incubated 
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with nanobeads at 37°C for overnight to allow internalization. Next day, the cells 
were washed with PBS to remove unbound nanobeads. Cells were cultivated for 
an additional day before the apoptotic cell amount was measured in a SubG1 test. 
In SubG1 test internucleosomal DNA fragmentation is detected using propidium 
iodide. 
Results 
 
 48 
a b
c d
6. RESULTS 
6.1. Selection of model test system and tools 
The aim of the project was to generate ligand-modified VSV-G proteins for 
targeting of tumor cells with expression of a surface tumor-associated antigen. In 
this project we choose prostate cancer as the model system and it’s “Prostate 
Stem Cell Antigen (PSCA)” as the pilot target. PSCA expression is highly 
restricted to the prostate tissue in male with some expression in bladder and 
colon. Moreover, in first experiments we showed the presence of PSCA on the 
surface of glioblastoma cells obtained from surgery samples of Glioblastoma 
Multiforme (GBM) patients (Figure 9). We have also generated PSCA-positive 
HEK293 cells for our analyses. A GPI-anchored PSCA expressing vector was 
transfected into HEK293wt cells and the PSCA-positive cells were selected using 
Geneticin. 
 
PSCA-negative HEK293wt cells, and HEK293-PSCA cells and GBM cells from patient (4T1) were 
stained natively with anti-PSCA antibody and sheep anti-mouse Cy3 antibody. PSCA-positive cells 
were detected with flow cytometry (marked as M1) (a, b). PSCA-staining was also observed for 
4T1 by indirect immunofluorescence using the same antibody combination as in flow cytometry 
detection. c: PSCA expression on natively stained 4T1 cells. d: 4T1 cells were stained with 
Hoechst 33342 and overlay is displayed. (a,b): open area: HEK293wt cells; gray area: HEK293-
PSCA cells. 
Figure 9. PSCA expression in GBM cells from patient. 
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6.2. Generation of scFv anti-PSCA / VSV-G fusion protein for targeted gene 
delivery 
The VSV-G mediates infection of a broad range of cells and thus despite the 
advantages of higher stability and high titer, VSV-G-pseudotyped particles are not 
suitable for selective targeting purposes. VSV-G fusion proteins were generated 
that were composed of a single-chain variable antibody fragment against PSCA 
and VSV-G protein. ScFv anti-PSCA (AM-I) was provided by Dr. Agnieszka 
Morgenroth at the Institute of Immunology (Dresden). AM-I was fused to VSV-G at 
the N-terminus. VSV-G is transported to the cell surface only as correctly folded 
trimers. To investigate the effect of fusion of AM-I to VSV-G, several different 
fusion proteins consisting of different VSV-G proportions and the scFv AM-I were 
generated. AM-I was fused either directly or with a small (5 amino acid-long) linker 
to VSV-G (Figure 10A and B). Besides, two more fusion proteins were produced in 
which AM-I was linked via an additional 7 long-long linker to N-terminally truncated 
VSV-G protein (Figure 10C and D). 
 
ScFv anti-PSCA was fused to the N-terminus of full-length VSV-G directly (A) or via a 5amino acid 
long linker (B). Two constructs (pAMI-L-sG1 and pAMI-L-sG2) contained VSV-G proteins, which 
were generated by N-terminal deletions of VSV-Gwt (C and D). 
Figure 10. Schematic illustration of scFv anti-PSCA / VSV-G fusion proteins. 
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6.2.1. Intracellular and surface expression of scFv anti-PSCA/ VSV-G 
proteins 
In first experiments we transfected the different scFv-AMI-VSV-G constructs in 
HEK293TZ cells and analyzed the expression of the fusion proteins by indirect 
immunofluorescence analysis. Only the modified protein expressed on cell surface 
can be packaged into viral particles. VSV-G depends on correct folding and 
trimerization for transport to the cell membrane. Intracellular and surface stainings 
were performed: For intracellular staining, transfected HEK293T cells were 
permeabilized and fixed. Cells were then stained with anti-VSV-G antibody directly 
coupled to Cy3 recognizing a cytoplasmic epitope in VSV-G (Figure 11).  
 
HEK293T cells were transfected with VSVG-AMI fusion protein-encoding plasmids. 
Transfections were conducted at 37°C (A) or 32°C (B). VSVG staining was performed on 
fixed and permeabilized cells with anti-VSV-G antibody coupled to Cy3. In both cases, 
staining from 293T cells transfected with plasmids encoding a, g: mock transfected; b, h: 
pcz-VSV-G wt; c, i: pAMI-G; d, j: pAMI-L-G; e k: pAMI-L-sG-1; f, l: pAMI-L-sG-2. 
Figure 11. Intracellular staining of HEK293T cells. 
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The surface staining of the AMI–VSVG fusion proteins was investigated by the use 
of an anti-VSV-G antibody (17-2-21-4), which binds to the extracellular domain of 
VSV-G and secondary anti-mouse Ig F(ab)’2-Cy3 (Figure 12A). A DNA counter-
staining was performed with Hoechst 33342. The ectopically expressed fusion 
proteins were easily detected by intracellular staining. However, none of them was 
detectable on the plasma membrane. Prompted by this observation, we 
considered that the secondary or tertiary protein structure of the modified proteins 
was affected. Therefore, we decided to analyze the subcellular localization of the 
VSV-G constructs at a lower temperature. It is well known, that temperature-
sensitive mutants of VSV-G experience problems either in folding or trimerization 
steps and are, therefore, not transported beyond the endoplasmic reticulum. 
However, this phenotype can be rescued by lowering the temperature to 
permissive temperatures, which allow correct folding or tolerate folding failures 
and enable subsequent transport of the protein to the cell membrane. 
Unfortunately, the intracellular transport could not be rescued for any of the AMI-
VSV-G fusion proteins (Figure 12B). Consequently, studies with the AMI-VSV-G 
fusion proteins were not further pursued. 
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HEK293T cells were transfected with VSVG-AMI fusion protein-encoding plasmids at 37°C (A) or 
32°C (B) with a, b: mock transfected; c, d: pcz-VSV-G wt; e, f: pAMI-G; g, h: p-AMI-L-G; i, j: pAMI-
L-sG1; k, l: pAMI-L-sG2. Staining was performed natively with anti-VSV-G antibody 17-2-21-4 and 
a Cy3-coupled goat anti-mouse antibody. DNA staining was performed with Hoechst 33342.  
Figure 12. The extracellular staining of HEK293T cells. 
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6.3. Generation of epitope-modified VSV-G proteins 
Fusion of scFv against PSCA to VSV-G resulted in failure in transport of modified 
proteins to the cell surface. To eliminate the disruption in protein folding due to 
insertion of a large scFv molecule, modified VSV-G proteins were generated by 
inserting a small epitope in putative insertion-permissive sites. An epitope exposed 
on the surface of VSV-G can target the viral particle via linker molecules (such as 
antibodies or bispecific nanobeads), which bind both to the target cell and the viral 
particle. Nanobeads can be coupled to anti-epitope antibody and to an antibody 
recognizing an applicable tumor-associated antigen expressed on the tumor cell 
surface.  
6.3.1. Selection of permissive sites in VSV-G protein for epitope insertion 
Modification of VSV-G for selective targeting without interfering with its functions 
required identification of permissive sites in the protein. Epitope length may play a 
role in folding since the protein structure has a limited flexibility and cannot tolerate 
at every position any insertion. Any complication in folding will have its 
consequences in expression and function of the protein. Two different epitopes 
were chosen. The first epitope to be inserted was the ten amino acid long myc 
epitope (EQKLISEEDL). The myc epitope is commonly used to track proteins 
since it does generally not interfere with protein folding and function, and high-
affinity anti-myc antibodies are available. The second epitope, the so-called La 
epitope consists of eighteen amino acids (EFEALKKIIEDQQESLNK) and was 
provided by Prof. M. Bachmann (Institute of Immunology, Dresden). The eighteen 
amino acid long La epitope is deduced from a region in the La protein to which 
high affinity antibodies were raised by Prof. M. Bachmann’s group. Epitope 
insertion sites were chosen on the same basis as the myc-epitope insertion sites. 
An ideal permissive site must allow insertion of an epitope without disturbing the 
folding, assembly into viral particles, virus internalization and subsequent fusion 
events. For this reason, VSV-G protein ectodomain sequences from VSV Indiana 
serotype strains and mutants were compared [175]. From the sequence 
comparison several non-conserved sites were identified as potential epitope-
insertion permissive sites (Table 10), among which some located to neutralizing 
epitope sequences [176]. Moreover, amino acid position 17 in the precursor 
protein, which corresponds to the N-terminus of the mature protein, was included. 
An additional site at position 28 was chosen since epitope insertion at a close-by 
position was shown to be well-tolerated [147]. The epitope-modified VSV-G 
proteins were named by the amino acid number in precursor G protein (prior to 
proteolytic cleavage of 16 amino acid-long signal sequence in ER) after which the 
epitope is inserted. Table 11 depicts the designations of the modified VSV-G 
proteins with the positions of epitope insertion.  
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259-260275-276La VSV G La 275
193-194209-210LaVSV G La 209
15-1631-32LaVSV G La 31
1-217-18LaVSV G La 17
262-263278-279mycVSV G myc 278
250-251266-267mycVSV G myc 266
192-193208-209mycVSV G myc 208
12-1328-29mycVSV G myc 28
1-217-18mycVSV G myc 17
Mature VSV GPrecursor VSV G
Position of amino acid residues
flanking the insertion in theEpitopeDesignation
SS/TTTTTT281
C/W/SC/W/SSSSSS279
A/GGAAAAA277
V/LA/PPPPPP267
FL/FFFFFF266
RRERGGG209
tsG31-
PC
tsG31-
PB
tsG31-
PA
tsG31OrsayMudd
Summe
rs
San 
Juan
Amino
acid
position
 
 
Accumulation of amino acid mutations in VSV-G protein from persistent infection isolates. Amino 
acid numbering was based on the precursor protein. tsG31 is a temperature mutant derived from 
VSV-G San Juan. tsG31-PA, tsG31-PB and tsG31-PC were derived from nude mice persistently 
infected with tsG31 [175] 
 
Table 10. Sequence comparison of VSV-G (Indiana) strains. 
Table 11. Nomenclature of epitope-modified VSV-G proteins and the epitope insertion 
positions. 
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6.3.2. Insertion of c-myc epitope in permissive sites into VSV-G ectodomain  
The myc epitope insertions were accomplished using the PCR-Based Site-
Directed Mutagenesis Kit (Stratagene) according to manufacturer’s instructions. 
For each site, VSV-G protein sequence in pcz-VSV-Gwt plasmid was amplified 
using a pair of primers introducing c-myc epitope and PstI restriction site (inserting 
in total of 33 nucleotides).  
6.3.2.1. Intracellular staining of myc-modified VSV-G-expressing cells 
HEK293T cells were transfected at 37°C with myc epitope-modified VSV-G protein 
encoding vectors. Cells were then stained for VSV-G expression. Transfected cells 
were fixed and permeabilized and stained with anti-VSV-G antibody coupled to 
Cy3. Figure 13 shows the protein expression in transfected cells. Effect of 
transfection temperature on protein expression was analyzed by transfection of 
cells also at 32°C and performing the same staining. VSV-G wt as well as all 
modified VSV-G proteins were detectable in transfected cells at both 
temperatures. 
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Intracellular staining of fixed and permeabilized HEK293T cells transfected with VSVG wt or VSV-G 
myc modified protein encoding plasmids was performed with anti-VSVG antibody (P5D4) coupled 
to Cy3. a, g: with VSV-G wt; b, h: with VSV-G myc-17; c, i: with VSV-G myc-28; d, j: with VSV-G 
myc-208; e, k: with VSV-G myc-266; f, l: with VSV-G myc-278 encoding vector. a-f: Transfection at 
32°C. g-l: Transfection at 37°C. 
Figure 13. Intracellular expression of myc-modified VSV-G. 
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6.3.2.2. Surface expression of myc-modified VSV –G proteins 
Targeted gene delivery using linker molecules requires that the c-myc epitope is 
readily exposed on the viral particles. Therefore, first of all the surface expressions 
of modified envelope proteins on natively stained HEK293T cells were detected. 
Transfections were performed both at permissive (32°C) and restrictive (37°C) 
temperatures. Cells were stained first with Hoechst 33342 to visualize the nucleus. 
VSV-G staining was performed with anti-VSV-G antibody (17-2-21-4, kind gift of 
Prof. Grünberg, University of Geneva, Switzerland) recognizing an epitope in the 
extracellular domain of VSV-G. As expected, the VSV-G wt protein was readily 
detected on the cell surface. Interestingly, also the modified VSV-G myc 17 and 
VSV-G myc 278 proteins were detectable on the cell surface at both restrictive and 
permissive temperatures. However, the constructs VSV-G myc 28 was only 
detectable when the transfection was performed at the permissive temperature 
(Figure 14; a-c, f, g-h, l). The modified proteins VSV-G myc 208 and VSV-G myc 
266 were not detected on the cell surface at both temperatures. (Figure 14; d-e, i-
k).  
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Native staining of non-fixed HEK 293T cells transfected with VSVG wt or VSV-G myc modified 
protein encoding plasmids was performed with anti-VSVG antibody (17-2-21-4) and as secondary 
antibody goat anti-mouse Ig F (ab')2 antibody coupled to Cy3. a, g: with VSV-G wt; b, h: with VSV-
G myc-17; c, i: with VSV-G myc-28; d, j: with VSV-G myc-208; e, k: with VSV-G myc-266; f, l: with 
VSV-G myc-278 encoding vector. a-f: Transfection at 32°C. g-l: Transfection at 37°C. DNA counter 
staining was performed prior to staining with Hoechst 33342.  
Figure 14. Surface expression of myc-modified VSV-G. 
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6.3.2.3. Detection of myc epitope in myc-modified VSV-G proteins  
A crucial prerequisite for a nanobead-mediated selective retroviral transduction is 
the accessibility of the c-myc epitope on the viral particles. Therefore, HEK293T 
cells were transfected with VSV-G wt or VSV-G myc protein-encoding vectors and 
were stained natively with an anti-myc antibody directly coupled to Alexa 488. 
Transfections were performed at permissive and restrictive temperatures, 
respectively, in order to analyze temperature-mediated effects on the exposition of 
the myc epitope. As expected, in VSV-G wt-expressing cells no positive staining 
was observed. On the other hand, VSV-G myc 17, VSV-G myc 278 proteins were 
detected at both incubation temperatures, whereas VSV-G myc 28 was only 
detected on cells which were incubated at 32°C. These results closely resemble 
the native staining obtained with the 17-2-21-4-VSV-G antibody. The two modified 
proteins, VSV-G myc 208 and VSV-G myc 266, which were not detectable on cell 
surface at both temperatures, also did not expose the myc epitope at both 
temperatures (Figure 15). Table 12 summarizes the results of expression patterns 
of the myc epitope-modified VSV-G proteins. 
Results 
 
 60 
a
b
c
d
e
f
g
h
i
j
k
l
 
HEK293T cells transfected with VSV-G wt and VSV-G myc modified proteins-encoding plasmids: a, 
g: VSV-G wt; b, h: VSV-G myc 17; c, i: VSV-G myc 28; d, j: VSV-G myc 208; e, k: VSV-G myc 266; 
f, l: VSV-G myc 278. Surface expression of proteins was detected by native staining with anti-myc 
antibody coupled to Alexa 488. DNA counter staining was performed with Hoechst 33342. 
Transfections were performed either a-f: at permissive temperature 32°C or g-l: at restrictive 
temperature 37°C.  
Figure 15. Availability of myc epitope on myc-modified VSV-G. 
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Also given is the accessibility of myc epitope by anti-myc antibody in native staining. ts: 
Temperature-sensitive expression, where protein or the epitope was only detectable at 32°C but 
not at 37°C. ts= temperature sensitive. 
6.3.3. Insertion of La epitope in VSV-G ectodomain 
6.3.3.1. Intracellular expression of La epitope-modified VSV-G proteins 
HEK293wt cells were transfected with pMD2.G-La plasmids at 32°C or 37°C. 
Fixed and permeabilized cells were stained with Cy3 coupled anti-VSV-G antibody 
(Sigma). The cells were observed and pictures were taken with Zeiss LSM Meta 
510 Laser Scanning Confocal Microscope. Figure 16 illustrates the intracellular 
expression of La-modified VSV-G proteins.  
+++VSV-G myc 278
--+VSV-G myc 266
--+VSV-G myc 208
tsts+VSV-G myc 28
+++VSV-G myc 17
-++VSV-G wt
myc epitope 
accessibility
Surface 
expression
Intracellular 
expression
Designation
Table 12. Overview of results with myc-modified VSV-G proteins. 
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HEK293wt cells transfected at 32°C (a-e) or 37°C (f-j) with La-modified VSV-G-encoding plasmids: 
a, f: VSV-G wt; b, g: VSV-G La 17; c, h: VSV-G La 31; d, i VSV-G La 209; e, j VSV-G La 271. Fixed 
and permeabilized cells were stained with anti-VSV-G antibody coupled to Cy3.  
Figure 16. Intracellular expression of La-modified VSV-G. 
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6.3.3.2. Surface expression of La epitope-modified VSV-G proteins 
HEK 293wt cells transfected with La-modified VSVG encoding plasmids were 
analyzed for the surface expression. HEK293wt cells were transfected at 32°C or 
37°C with La-modified VSV-G-encoding plasmids. Cells were first stained for DNA 
with Hoechst 33342 and then for La epitope with 4B6 antibody. The staining was 
performed on non-fixed, non-permeabilized cells. Subsequently, cells were fixed 
and pictures were taken with Zeiss LSM Meta 510 Laser Scanning Confocal 
Microscope (Figure 17). Among the four La-modified VSV-G proteins, only two 
(VSV-G La 209 and VSV-La 271) were expressed on the plasma membrane. 
 
HEK293wt cells transfected with La-modified VSV-G-encoding plasmids at 37°C (a-e) and 32°C (f-
j). DNA counter staining was performed with Hoechst 33342. La-epitope was detected using anti-
VSV-G antibody (17-2-21-4) and goat anti-mouse Cy3 antibody. a, f: VSV-G wt ; b, g: VSV-G La 
17; c, h: VSV-G La 31; d, i: VSV-G La 209; e, j: VSV-G La 271. 
Figure 17. Surface expression of La-modified VSV-G. 
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6.3.3.3. Accessibility of La epitope on La-modified VSV-G proteins  
Next, the accessibility of the La epitope was analyzed. HEK293wt cells transfected 
with VSV-G wt or VSV-G La protein-encoding vectors. First, the DNA counter-
staining was performed with Hoechst 33342. Then the cells were stained natively 
with a monoclonal anti-La antibody (4B6, provided by Prof. Bachmann, Dresden) 
and goat anti-mouse secondary antibody coupled to Cy3. Only the VSV-G protein 
modified at amino acid position 271 exposed La epitope, and it did so only at 32°C 
(Figure 18). Table 13 summarizes the feature of La-modified VSV-G proteins. 
 
HEK293wt cells transfected with La-modified VSV-G-encoding plasmids. DNA counter staining was 
performed with Hoechst 33342 prior to anti-La staining. La-epitope was detected with anti-La 
antibody (4B6) and goat anti-mouse Cy3 secondary antibody. Transfections were performed at 
32°C (a-e) and 37°C (f-j). a, f: VSV-G wt detected with anti-La antibody; b, f: VSV-G La 17; c, h: 
VSV-G La 31; d, i: VSV-G La 209; e, j: VSV-G La 271. 
Figure 18. Detection of La epitope on VSV-G La-expressing cells. 
Results 
 
 65 
Only at 37oC++VSV G La 275
-++VSV G La 209
--+VSV G La 31
--Only at 37oCVSV G La 17
-++VSV G wt
La epitope 
accessibility
Surface
expression
Intracellular
expression
Designation
 
Also given is the accessibility of La epitope. The mutants whose specified feature was dependent 
on the transfection temperature are indicated with the temperature at which positive staining was 
observed. 
6.4. Fusogenic activity of epitope-modified VSV-G proteins 
Onset of the VSV-G-mediated entry into target cells is the VSV-G binding to the 
cellular receptor. Bound virus is then internalized into the endosomal vesicles, 
which in turn acidifies. The acidic pH leads to a conformational change in VSVG 
protein. In this low-pH form of VSVG, the fusion peptide is exposed and this 
results in the fusion of viral membrane with that of the endosomal vesicle. This 
fusion step is critical for the success of gene delivery using VSV-G-pseudotyped 
viral particles. Therefore, the fusogenic capacities of the modified VSV-G proteins, 
which were transported to the cell membrane and exposed the respective epitope, 
were evaluated. To resemble the acidic conditions present in the endosomal 
vesicle, the cells were incubated with PBS, whose pH was adjusted to a certain 
value. HEK293T cells were co-transfected with VSV-G wt or modified VSV-G- and 
EGFP-encoding plasmids. A pH range (pH 5.0 to pH 7.5 in 0.5 intervals) including 
the optimal pH of VSV-G wt was tested. Transfections were performed both at 
permissive and restrictive temperatures and fusion assay was performed. 
Syncytium formation was observed and documented with Zeiss Axiovert 200M 
microscope.  
6.4.1. Membrane fusion assay with myc-modified VSV-G mutants 
The results of the fusion assay at representative pH values are depicted in Figure 
19 for myc-modified VSV-G proteins. VSV-G wt has an optimal fusion pH range of 
5.8 to 6.2 and the temperature of transfection does not affect its fusogenic 
capacity. VSV-G myc 17 was fusogenic at both permissive and restrictive 
Table 13. The overall summary of intracellular and surface expression of La-modified VSV-G 
proteins. 
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temperature with an optimum pH of 5.5 (Table 14). As expected, VSV-G myc 28, 
which was only transported to the cell surface at 32°C, induced membrane fusion 
also only at this temperature. Like VSV-G myc 17, VSV-G myc 28 had an optimal 
fusion pH lower than that of VSV-G wt. Interestingly VSV-G myc 278 exhibited no 
fusion at any pH regardless of the temperature although this protein was 
transported to the cell surface at both 32°C and 37°C. Consequently, VSV-G myc 
278 protein was not included in further experiments. 
 
HEK 293T cells were co-transfected at 37 °C (A,C) and 32°C (B,D) with EGFP and VSVG (wt or 
myc-modified) protein-encoding plasmids. 2 days after transfection, fusion was induced by 
incubating the cells with pH-adjusted PBS for 10min at RT. Cells were then incubated with fresh 
culture medium for 3hours at 32°C or 37°C, before repeating the procedure. Finally, cells were 
fixed and observed with Zeiss Axiovert 200M microscope. For each transfection and pH value 
three random areas are photographed only one of which is depicted in the figure. For 
determination of the optimal fusion pH, a pH range from 5.0 to 7.5 in 0.5 point intervals was 
tested. Here pH values A, B: 5.5; C, D: 7.0 are illustrated. Cells were transfected with plasmids 
encoding a: EGFP; b: VSVG wt; c: VSV-G myc 17; d: VSVG myc 28; e: VSV-G myc 278. Fused 
cells display distinguished morphology; several nuclei concentrated in the centre of the syncytium 
(stars). 
Figure 19. Fusion assay with the myc-modified VSV-G proteins. 
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Fusogenic capacities of VSV-Gwt- and myc-modified VSV-G proteins were analyzed in pH range 
5.0-7.5 (in 0.5 intervals) and at 32°C (A) and 37°C (B) are summarized. 
6.4.2. Membrane fusion assay with La-modified VSV-G mutants 
Next, the fusion capacity of VSV-G La 271 protein was analyzed on transfected 
cells. The protein was subjected to the same fusion assay as the myc-modified 
VSV-G proteins. Unfortunately, the VSV-G La 271 was not capable of inducing 
cell-to-cell fusion (Figure 20 and Table 15). Therefore, this mutant was not 
included in further analyses. 
Table 14. The fusogenic activities of VSV-G proteins. 
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HEK 293T cells were co-transfected at 32 °C (A, C) and 37°C (B, D) with EGFP and VSVG (wt or 
La-modified) protein-encoding plasmids. 2 days after transfection, fusion was induced by 
incubating the cells with pH-adjusted PBS for 10min at RT. Cells were then incubated with fresh 
culture medium for 3hours at 32°C or 37°C, before repeating the procedure. Finally, cells were 
fixed and observed with Zeiss Axiovert 200M microscope. For each transfection and pH value three 
random areas are photographed only one of which is depicted in the figure. For determination of 
the optimal fusion pH, a pH range from 5.0 to 7.5 in 0.5 point intervals was tested. Here pH values 
A, B: 5.5; C, D: 7.0 are illustrated. Cells were transfected with plasmids encoding a: EGFP; b: 
VSVG wt; c: VSVG La 271. Fused cells display distinguished morphology; several nuclei 
concentrated in the centre of the syncytium (stars). 
 
VSV-G wt and La epitope-modified VSV-G protein (VSV-G La 271) was analyzed for fusogenic 
capacity in the pH range 5.0-7.5. Fusion assays were performed at 32°C (A) and 37°C (B). 
Figure 20. Fusion assay with La-modified VSV-G proteins. 
Table 15. The fusogenic capacity of La-modified VSV-G proteins. 
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6.5. Generation of viral particles pseudotyped with mutant VSV-G proteins 
6.5.1. Assembly of VSV-G protein into viral particles (packaging) 
The fusogenic myc epitope-modified G proteins were next studied with respect to 
their capacity to be incorporated into viral particles. Virus assembly was performed 
at 32°C, which enabled packaging of not only VSV-G wt and VSV-G myc 17 but 
also the temperature-sensitive protein VSV-G myc 28. The retroviral particles were 
generated as described in chapter 5.4.2 (Figure 21).  
 
Packaging cells are co-transfected with three vectors to generate replication-deficient viral particles. 
One plasmid encodes the gene of interest, which also contains the packaging signal, one plasmid 
codes for envelope protein and the third plasmid encodes gag-pol proteins. 
 
Total cell lysates from the packaging cells were prepared and analyzed by 
Western blotting. The membrane was incubated with an anti-VSV-G antibody and 
secondary rabbit anti-mouse Ig HRP antibody. Detection was accomplished via 
chemiluminescence. All packaging cells except the packaging without envelope 
protein (∆env; pHIT 60 and pcz-CFG2-fEGFPf co-transfection) expressed the 
VSV-G protein (Figure 22).  
Figure 21. Three-vector packaging system according to Soneoka et al. [3]. 
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HEK293T cells were co-transfected with pHIT 60, pcz-CFG2-fEGFP alone (∆env) or with VSV-G wt 
or myc-modified VSV-G. Cell lysates were separated by SDS-PAGE and proteins were transferred 
to PVDF membranes. Proteins were detected with anti-VSV-G antibody and rabbit anti-mouse Ig 
HRP antibody using ECL. 
6.6. Concentration and purification of retroviral particles 
6.6.1. Concentration of viral particles via ultracentrifugation 
The viral particles were concentrated form the packaging cell medium by 
ultracentrifugation 100.00g with a Beckman Coulter Ultracentrifuge (SW40Ti or 
SW28 rotor) at 4°C for 2hrs. Following ultracentrifugation, the supernatant was 
discarded carefully and the viral particles were re-suspended in SDS sample 
buffer for SDS-PAGE analysis or in culture medium for further use. The viral 
particles were analyzed by 10% SDS-PAGE and blotted onto PVDF membranes. 
Presence of viral particles was demonstrated (Figure 23) using the anti-VSV-G 
(P5D4) and horseradish peroxidase (HRP)-coupled rabbit anti-mouse Ig 
antibodies.  
Figure 22 Immunoblot analysis of total cell lysates from packaging cells.. 
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Ultracentrifuge-concentrated supernatants from packaging cells were analyzed. Packaging cells 
were co-transfected with pHIT 60, pcz-CFG2-fEGFP alone or with VSV-G wt or myc-modified VSV-
G. Viral particles were separated by SDS-PAGE and proteins were transferred to PVDF 
membranes. Proteins were detected with anti-VSV-G antibody and rabbit anti-mouse Ig HRP 
antibody with ECL Plus using LAS 3000 (Fuji). ∆env: Packaging cells were co-transfected only with 
pHIT60 and pcz-CFG2-fEGFPf. 
6.6.2. Purification of myc-modified-viral particles  
Anti-myc antibody-coupled magnetic beads (Miltenyi Biotec) were used to capture 
retroviral particles pseudotyped with the myc-modified envelope from the 
packaging cell supernatant. Eluates from the magnetic bead purification were first 
analyzed with the anti-VSV-G antibody P5D4 and rabbit anti-mouse Ig HRP 
antibody. Purified myc-modified viral particles displayed a protein band around 
67kDa corresponding to VSV-G protein Figure 24A. As expected there was no 
band representing the VSV-G protein in the supernatants of cells which were not 
transfected with the wild-type envelope protein. The secondary anti-mouse HRP 
conjugate also detects the heavy and the light chains of anti-myc antibody, which 
was coupled to the magnetic beads and was, probably, co-eluted by the hot 
sample buffer. There is no immunoreactivity against VSV-G wt-pseudotyped 
retroviral particles, since they are washed away from the anti-myc column. To 
demonstrate that the envelope proteins, which were observed in viral eluates, 
represent viral particles and not viral envelope proteins shed from the packaging 
cells, the membrane was stripped an re-probed with a polyclonal goat anti-p30 
serum. Figure 24B shows the presence of the p30 capsid protein in the modified-G 
protein pseudotyped viral eluates, whereas no bands corresponding to that protein 
were observed in samples from packaging without envelope or with VSV-G wt. An 
Figure 23. Immunoblot analysis of viral particles following ultracentrifugation. 
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additional band of ~65kDa was detectable in the samples, which was probably the 
precursor of capsid protein, p65gag. Also other anti-MLV capsid antibodies have 
been described that recognize this precursor [177].  
 
Eluates from purification were separated in SDS-PAGE and proteins were transferred to PVDF 
membrane. A: VSV-G proteins in eluates were detected with anti-VSV-G antibody and HRP 
conjugated rabbit anti-mouse Ig antibody. The same membrane was used to detect the capsid 
protein after stripping under stringent conditions and overnight blocking. B: Capsid protein 
detection was conducted with anti-p30 serum and HRP conjugated rabbit anti-goat antibody. Blots 
were visualized in both cases with ECL Plus visualization kit and light-sensitive Hyperfilm. 
6.7. Transduction of HEK293T cells with VSV-G–pseudotyped retroviral 
particles 
VSV-G wt-pseudotyped viral particles have a broad target cell range owing to a 
still undefined ubiquitously expressed cellular receptor. Therefore, it was 
necessary to analyze whether the epitope insertion has any effect on the wild-type 
tropism and transduction efficiency. Briefly, VSV-G wt- or modified VSV-G-
pseudotyped retroviral particles encoding EGFP were packaged. 48hrs and 72hrs 
after transfection supernatants were harvested and pooled. One ml supernatant 
was used for transduction of the HEK293T cells in the presence of 8µg/ml 
Polybrene. The transduction efficiency was determined 3 day after transduction by 
FACS. The packaging was performed at 32°C and the transduction was done at 
both 32°C and 37°C. Figure 25 shows the transduction efficiencies on HEK293T 
cells, which were transduced at 37°C (Figure 25 a, c, e, g) or 32°C (Figure 25 b, 
d, f, h). The average efficiencies of transduction at 32°C and 37°C using retroviral 
particles produced at 32°C are illustrated in Figure 26. The modified retroviral 
particles displayed lower transduction efficiencies than the wild-type envelope-
Figure 24. Immunoblot analysis of packaging cells supernatant purified with anti-myc 
antibody coupled-magnetic bead. 
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containing particles. However, the particles displayed similar transduction 
efficiencies both at 37°C and 32°C.  
 
Packaging of HEK293T cells was performed at 32°C. For packaging pHIT60 and pcz-CFG2-
fEGFPf plasmids were used either alone (a, b: ∆env) or with VSVG encoding plasmids where c, d: 
VSV-Gwt; e, f: VSV-G myc 17; g, h: VSV-G myc 28. The transduction experiments were 
performed at either 37°C (a, c, e, g) or 32°C (b, d, f, h). 
Figure 25. Transduction efficiency of retroviral particles packaged at 32°C. 
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For each envelope protein the mean transduction efficiency of three independent experiments is 
shown. Transduction temperatures are indicated. ∆env: The packaging without envelope protein. 
6.7.1. Effect of anti-myc antibody on transduction mediated by myc-modified 
retroviral particles  
Next we analyzed whether anti-myc antibody binding can inhibit or reduce 
transduction efficiency with myc-modified viral particles. The virus production was 
conducted at 32°C and transduction was performed at 37°C in the presence of one 
of the following antibodies at a final concentration of 1µg/ml: neutralizing anti-
VSVG antibody (8G5, generous gift from Prof. Lyles), anti-myc antibody 
(Invitrogen) or anti-Xpress tag antibody (Invitrogen), which served as an isotype-
matched control. Transduction experiments were carried out in the presence of 
8µg/ml Polybrene (final concentration). In Figure 27 results are depicted as 
normalized to the transduction efficiency obtained with the anti-Xpress antibody 
Transduction by MLV(G-wt) particles was inhibited by the neutralizing anti-VSV G 
antibody but was not affected significantly by either anti-myc or anti-Xpress 
antibodies. On the other hand, transduction with MLV(G-myc 17) was not only 
inhibited by the neutralizing anti-VSV G antibody but also was reduced to 50% 
when anti-myc antibody was added to the viral particles. The envelope protein 
VSV-G myc 28-mediated transduction was also diminished by the anti-myc 
antibody.  
Figure 26. Average transduction efficiency of viral particles packaged at 32°C. 
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HEK293T cells were transduced with retroviral particles pseudotyped with VSV-G wt, VSV-G myc 
17 or VSV-G myc 28. Transduction was performed in the presence of 8µg/ml Polybrene (final 
concentration), and 1µg/ml of one of the following antibodies: anti-VSVG (neutralizing), anti-myc or 
anti-Xpress. Anti-Xpress antibody is from the same isotype as the anti-myc antibody and has no 
binding counterpart either on the viral particle or HEK293T cells. Black column: anti-Xpress 
antibody; white column: anti-myc antibody; striped column: anti- VSV-G antibody. Results from a 
representative experiment out of three are shown. 
6.8. Effect of nanobeads on the transduction efficiency of myc-modified 
VSV-G expressing viral particles 
The myc-modified retroviral particles can be captured by anti-myc coupled 
nanoparticles and targeted to PSCA-expressing cells when the nanoparticles are 
also conjugated to anti-PSCA antibodies. In order to analyze this approach and 
suggest targeted gene delivery method using modified VSV-G proteins, we used 
superparamagnetic nanoparticles with a diameter of 200nm and coated with a 
polysaccharide matrix. These nanoparticles were chemically coupled to 
monoclonal anti-myc and anti-PSCA antibodies. First of all, the nanobeads were 
analyzed for their ability to bind to PSCA on engineered and native PSCA-
expressing cells. Next, the binding of nanobeads to the myc-modified viral 
particles was investigated. 
6.8.1. anti-PSCA/anti-myc superparamagnetic nanobeads (NB) 
The anti-PSCA- and anti-myc antibody-coupled magnetic beads can play a vital 
role in targeted transduction strategy. As bridging molecules, nanobeads must be 
able to bind PSCA-positive target cells and the myc-epitope of the modified VSV-G 
Figure 27. Transduction of HEK293T cells in the presence of anti-myc antibody. 
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on the virus particle simultaneously. Before scrutinizing the function of nanobeads 
as linker molecules, first sole interactions of antibodies with their respective targets 
must be studied.  
6.8.2. Binding of anti-PSCA/anti-myc nanobeads onto PSCA-positive cells 
The PSCA-negative and -positive cells were incubated with the nanobeads and 
the binding was detected with sheep anti-mouse Cy3 antibody recognizing the 
antibodies on the nanobeads, which are both of mouse origin. Cells lines tested 
included PSCA-negative HEK293wt cells, HEK293-PSCA cells engineered to 
express membrane anchored PSCA, and bladder carcinoma cell lines HT1376 
and RT4, which natively express PSCA on their surfaces. Surface PSCA 
expression was confirmed for PSCA-positive cells by staining with anti-PSCA 
antibody 7F5 and anti-mouse IgG Cy3 under native conditions (Figure 28B). 
Specificity of the detection was demonstrated using isotype control as the primary 
antibody (Figure 28C). HEK293wt cells were devoid of any PSCA expression but 
HEK293-PSCA as well as RT4 and HT1376 expressed PSCA on the surface. In 
agreement with the PSCA expression, anti-PSCA/ anti-myc magnetic beads were 
able to bind only to PSCA-positive cells but not to PSCA-negative HEK293 wt 
(Figure 28A). 
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HEK293wt (a), HEK293-PSCA (b), HT1376 (c) and RT4 (d) cells were used to show A: binding of 
anti-PSCA/anti-myc magnetic beads to PSCA-positive cells after 240min incubation at 37°C. The 
staining was performed with sheep anti-mouse IgG antibody coupled to Cy3. B: surface PSCA 
expression on native cells using anti-PSCA antibody 7F5 and sheep anti-mouse IgG-Cy3. C: the 
absence of non-specific binding using isotype-matched control antibody and sheep anti-mouse 
IgG-Cy3. HEK293wt cells (black) were confirmed to be PSCA-negative. Isotype control antibody 
was used as negative control (green). 
Figure 28. Binding of anti-PSCA and anti-myc antibody-coupled nanobeads onto PSCA-
positive cells. 
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6.8.3. Effect of anti-PSCA/ anti-myc nanobeads on cell survival 
Gu et al. [172] and Saffran et al. [171] demonstrated that anti-PSCA antibodies 
induce apoptosis in the tumor cells. Therefore, we analyzed whether the anti-
PSCA antibodies coupled to the nanobeads induce apoptosis on PSCA-negative 
and –positive cells. We analyzed the fraction of cells undergoing internucleosomal 
DNA-fragmentation by a SubG1 analysis. As illustrated in Figure 29 nanobeads 
did not induce apoptosis in either PSCA-negative or PSCA-positive cells.  
 
PSCA-negative HEK293wt (a, e); and PSCA-positive cells HEK293-PSCA (b, f); RT4 (c, g); 
HT1376 (d, h) cells were analyzed. a-d: Cells were incubated with IgG1 isotype control antibody 
(control to the anti-PSCA and anti-myc antibodies bound to nanobeads). e-h: cells were incubated 
with anti-PSCA/ anti-myc nanobeads. DNA fragmentation was measure by propidium iodide 
staining. Apoptotic cells are indicated in the area M1 and the percentage of apoptotic cells are 
displayed on respective histogram. 
Figure 29. Effect of anti-PSCA/ anti-myc nanobeads on the survival of PSCA-negative and 
PSCA-positive cells. 
Results 
 
 79 
6.8.4. Binding of anti-PSCA/ anti-myc nanobeads onto myc-modified 
retroviral particles 
Since we revealed that the anti-PSCA/ anti-myc magnetic beads are able to bind 
PSCA-positive cells specifically, we analyzed in the next experiment the binding of 
the magnetic beads to the viral particles pseudotyped with myc-modified VSV-G 
proteins. The viral particles were harvested from packaging cells at 32°C and 
incubated with magnetic beads in an orbital shaker for 30min at 37°C. The mixture 
was then centrifuged at 14000 rpm at 4°C for 30min in a regular bench-top 
centrifuge. The pellet containing beads and virus bound to beads was used for 
SDS-PAGE and subsequent Western blotting. The associated virus was detected 
with the anti-p30 antibody (for the capsid protein of MLV) and the HRP-conjugated 
rabbit anti-goat IgG antibody (Figure 30). VSV wt-pseudotyped particles lacked the 
myc-epitope and therefore did not bind to the nanobeads. These particles were 
thus not precipitated into the pellet. On the other hand, the myc epitope-containing 
viral particles were detected as shown by the presence of ~30kDa band 
corresponding to the capsid protein. In conclusion, anti-myc/anti-PSCA nanobeads 
were capable of binding to the myc epitope and PSCA, separately. 
 
Supernatants containing viral particles were incubated with anti-PSCA / anti-myc nanobeads. The 
mixture was centrifuged to precipitate bead/virus complex. The pellet was analyzed by SDS-PAGE 
and western blot using anti-p30 serum and rabbit anti-goat IgG HRP antibody. The blot was 
developed with ECL Plus kit and visualization was performed with Fuji LAS 3000.  
Figure 30. Binding of anti-PSCA / anti-myc nanobeads to myc-modified viral particles. 
Results 
 
 80 
0
20
40
60
80
100
polybrene NB
6.8.5. Effect of nanobeads on transduction with VSV-G wt-pseudotyped 
particles 
To exclude any negative effects of the nanobeads on transduction efficiencies we 
mixed nanobeads to retroviral particles pseudotyped with wild-type VSV-G and 
transduced HEK293wt cells. For comparison we included non-treated particles. 
Figure 31 illustrates the mean transduction efficiencies of three experiments. The 
experiments revealed that the VSV-G wt mediated transduction efficiency was not 
influenced by the presence of nanobeads. 
 
Retroviral particles pseudotyped with VSV-Gwt were used to transduce HEK293wt cells in the 
absence or in the presence of nanobeads (NB). Polybrene was added only in the absence of 
nanobeads. 
6.8.6. Transduction with myc-modified viruses in the presence of nanobeads 
In the next experiment we sought to investigate whether the myc-modified 
retroviral particles were still infectious when bound to nanobeads. Virus production 
was performed at 37°C and the viral particles were concentrated 100-fold by 
ultracentrifugation. Virus titer was determined on HEK293wt cells to be 3x107 for 
VSVG wt–pseudotyped particles and 3x106 for VSV-G myc 17-pseudotyped 
particles. We then assumed that at least five myc-modified viral particles can bind 
to a single nanoparticle without completely covering the surface. These complexes 
made of 5 viruses and 1 nanobead act as a single virus because each such 
complex can get access to a single target cell. Therefore in calculating the 
multiplicity of infection (MOI) one complex was considered as a single virus and 
MOI of 3.4 was used for VSV-G myc17 particles. In case of VSV-G wt–
Figure 31. Transduction analysis with VSV-G wt-pseudotyped retroviral particles in the 
presence of nanobeads. 
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pseudotyped retroviral particles the amount of virus particles was kept constant. 
Since these viral particles do not bind to the nanobeads MOI was 17. As depicted 
in Figure 32, both wild-type and myc-modified VSV-G expressing particles were 
infectious on PSCA-negative and –positive cells. However there was no enhanced 
transduction on PSCA-positive cells.  
In a separate experiment we demonstrated the internalization of nanobeads 
selectively by PSCA-positive cells transduced with MLV(G-myc 17) particles. We used 
MLV(G-wt) and MLV(G-myc 17) particles for transduction in the excess of nanobeads. 
The transduced cells were cultivated for a week, in which the cells were splitted 
and washed intensively with PBS. Then the cells were re-suspended in PBS and 
dried on Whatman paper. The cells transduced with the MLV(G-wt) particles were 
not visible as well as the HEK293 cells transduced MLV(G-myc 17). However, 
HEK293-PSCA cells transduced with MLV(G-myc 17) were detectable as brown dots, 
which was due to the presence of brown-colored nanobeads (Figure 33).  
 
Viral particles concentrated 100x with ultracentrifugation were used for transduction. Transduction 
was performed either only with viral particles (Virus) or using viral particles incubated with the 
nanobeads (Virus +NB). The number of viral particles was kept constant therefore MOI was either 
3.4, except for c and d in the case of MLV(VSV-G wt) transduction. PSCA-negative HEK293wt (Black) 
and PSCA-positive HEK293-PSCA (white) cells were transduced. 
Figure 32. Transduction of PSCA-positive cells with myc-modified viral particles in the 
presence of nanobeads. 
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HEK293 (a) and HEK293-PSCA (b) cells were transduced with MLV(G-myc 17) particles in the 
presence of nanoparticles and cultured for a week. Later the cells were harvested in PBS and 
aliquots were dried on Whatman paper. 
Recently, Chan et al. [155] reported concentration of VSV-G wt pseudotyped 
lentiviral vectors, which gained biotinylated membrane from the packaging cells, 
via streptavidin-coated magnetic beads. In this study authors purified the lentiviral 
particles in the excess of nanobeads. We have repeated the transduction 
experiments, and this time used overload of nanobeads. The viral particles were 
mixed with the nanobeads and were used to transduce PSCA-positive and-
negative cells without prior concentration or purification. As depicted in Figure 34, 
the presence of nanobeads significantly inhibited the transduction with myc-
modified VSV-pseudotyped particles on both PSCA-positive and –negative cells.  
 
The retroviral particles were used alone (black and blue) or in the excess of nanobeads to 
transduce HEK293wt (Black and red) and HEK293-PSCA (blue and green) cells.  
Figure 33. Internalization of nanobead:virus complexes by PSCA-positive cells. 
Figure 34. Transduction efficiency of myc-modified retroviral particles in the presence of 
excess nanobeads. 
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We then purified myc-modified viral particles via incubation on a magnet. The viral 
particles were concentrated by ultracentrifugation (100fold) and titers were 
determined. Both VSV-Gwt and VSV-G myc 17-pseudotyped DsRed-expressing 
particles were incubated with 2fold excess of nanobeads and the nanobead: 
particle complexes were precipitated on a magnet for 1hr. the precipitate and the 
supernatant parts were used to transfected a mixed culture of PSCA-positive and 
–negative cells. For this experiment we generated PSCA-positive EGFP-
expressing cells by transient transfection of HEK293 cells with 
pRevCMV_PSCA_IRES2_EGFP vector. VSV-G wt-expressing particles were 
found to be only in supernatant but not in the precipitate (Figure 35). In case of 
MLV(G-myc 17) particles the transduction efficiency with the supernatant was the 
same as in the mock-transduced cells (Fig. 36e; transduced with medium from 
envelope deficient packaging). Although the viral titers were very low, we observed 
an increase in the transduction efficiency on PSCA-positive cells with the 
precipitate containing VSV-G myc 17-particles and nanobeads. We also confirmed 
these results by confocal laser scanning microscopy. The wild type VSV-G-
containing particles infected both PSCA-positive and –negative cells (Figure 36A). 
However, the purified MLV VSV G myc 17 particles showed a tendency to transduce 
PSCA-positive cells (Figure 36B).  
 
MLV(G-wt) (a, b) and MLV(G-myc 17) particles were incubated with nanobeads and particles bound to 
the nanobeads were precipitated on magnet. The supernatant from the purification (a, c) and the 
precipitate (b, d) were used to transduce HEK293 (Black column) and HEK293-PSCA (striped 
column) cells. 
Figure 35. Enhanced transduction of PSCA-positive cells with MLV
(G-myc 17)
 particles purified 
with nanobeads. 
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Retroviral particles encoding for DsRed were produced with (A) VSV-G wt or (B) VSV-G myc 17 
envelope protein. PSCA-positive EGFP encoding cells and PSCA-negative cells were transduced. 
(a): PSCA-positive cells expressing EGFP; (b): DsRed expressing transduced cells: (c): overlay of 
“a” and “b”; (d): DNA staining with Hoechst 33342. Stars indicate PSCA-positive transduced cells. 
Figure 36. Nanobead mediated-transduction of PSCA-positive cells with MLV(G-myc 17) 
particles. 
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7. DISCUSSION 
VSV-G is among the most commonly used envelope proteins for pseudotyping 
viruses [94,116] . VSV-G –pseudotyped MoMuLV vectors were shown to be highly 
stable and capable of infecting diverse cell types ranging from fish to mammals 
[94]. Retroviral particles containing VSV-G as envelope protein can be produced at 
high titers. All these characteristics indicate VSV-G as a useful tool for gene 
delivery purposes. However an anti-tumor gene therapy requires specificity to the 
target cell type. Therefore it is necessary to identify sequences in VSV-G which 
may tolerate modification and mutations and may be used for altering virus target 
tropism.  
In this project the aim was to generate modified VSV-G proteins and to evaluate 
their utility in targeted gene therapy. The evaluation was performed in six steps. 
First the expression of mutant protein in transfected cells was shown. Second the 
proteins were analyzed for the intracellular transport to the plasma membrane in 
transfected cells. Next the proteins, which were transported to the cell surface, 
were subjected to fusion assay, where the fusion of viral envelope with the 
endosomal vesicle membrane was simulated. Fourth step was the incorporation of 
mutant VSV-G proteins into viral particles, which was shown by Western blot 
analysis of supernatants from the packaging cells. Then infectivity of the viral 
particles pseudotyped with mutant proteins was examined. Last but not least, 
using nanoparticles the feasibility of the mutant VSV-G-pseudotyped viral particles 
for targeted gene delivery was assessed. 
7.1. Generation of modified VSV-G proteins 
7.1.1. Generation of scFv anti-PSCA / VSV-G fusion protein 
We have started this project with the generation of a fusion protein that consisted 
of a single chain antibody fragment against the tumor-associated antigen PSCA 
and VSV-G. ScFv anti-PSCA possesses the same binding specificity as the 
parental anti-PSCA antibody. ScFv molecules have only one binding part for their 
antigens and therefore have a lower binding force compared to the parental 
antibodies. ScFv anti-PSCA was fused N-terminally to VSV-G. Four different 
fusion proteins were cloned. Two of the proteins contained full-length VSV-G 
whereas the other two contained N-terminally truncated VSV-G proteins (Figure 
10). All four mutant proteins failed to be transported to the cell membrane (Figure 
12A). Normal cultivation of cell lines takes place at 37°C, at which also the 
transfection experiments were performed. However, there are examples of mutant 
VSV-G proteins whose surface expression is dependent on the temperature. 
These so-called temperature-sensitive mutants are misfolded at the restrictive 
temperature 37°C but this can be rescued when the temperature is lowered. None 
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of the scFv anti-PSCA / VSV-G fusion proteins was transported to the plasma 
membrane at 37°C and this failure in transport could not be rescued by lowering 
the incubation temperature to 32°C (Figure 12B).  
A single-chain antibody fragment has a molecular weight around 30kDa. Probably 
linking of such a big protein to the VSV-G was destructive to the protein folding. It 
is known that the only correctly folded trimers can leave the ER and be transported 
to the Golgi where post-translational modifications are processed [124]. In 2006 
Dreja et al. [149] inserted a scFv against human MHC-I and demonstrated the 
successful incorporation of the fusion protein into lentiviral particles. The authors 
performed the fusion also on the N-terminus of the mature VSV-G protein and 
although we have similar constructs (the two fusion proteins with full length VSV-
G) our results were rather different. The differences between the fusion proteins 
this study and those published by the authors are in the linker sequence and the 
leader peptide. The former may play a role in independent folding of both proteins 
allowing the correct conformation for each. The latter should not be the decisive 
factor for the failure of transport since the leader sequence used in our constructs 
is widely used in mammalian expression vectors for effective secretion of proteins. 
7.1.2. Generation of myc epitope modified VSV-G proteins 
The fusion of the scFv to the VSV-G protein resulted in a retention of the protein in 
the ER. Therefore we decided to modify VSV-G with a smaller sequence, which 
later can be used for targeting. VSV-G is known to be intolerant even to small 
epitope insertions or single amino acid substitutions [126,129,146,178]. Therefore, 
we compared the G protein sequences of VSV mutants and natural isolates (Table 
10). VSV-G protein has shown to be accumulate mutations also in antigenic 
epitopes [175]. From the comparison of six VSV strains it was possible to deduce 
four regions for epitope insertion (Table 11). Additionally the N-terminal part of the 
mature protein, namely the amino acid number 17 in the precursor protein, and 
another position at the N-terminus (amino acid 28) were included. All of the myc-
epitope modified VSV-G proteins were expressed in transfected cells (Figure 13) 
but only two of the myc-modified VSV-G proteins were transported to the plasma 
membrane (Figure 14). Moreover, a third mutant displayed a temperature-
sensitive phenotype. Here, the intracellular transport could be rescued by lowering 
the incubation temperature to 32°C (Figure 14). The other two mutants most 
probably aggregated in the ER and were only detected in the perinuclear regions 
of permeabilized cells. The mutants, which were transported to the cell membrane, 
also exposed the myc epitope (Figure 15). During the completion of this thesis 
work Roche et al. succeeded in the elucidation of the crystal structure of the low-
pH and the pre-fusion forms of the VSV-G protein [2,179]. This new information 
now enables a better understanding of the characteristics of our VSV-G mutants. 
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The low-pH crystal structure of VSV-G revealed four distinct domains (Figure 37). 
Domain I is composed of two segments, residues 1 to 17 and residues 310 to 383. 
Domain II is involved in trimerization of the top of the molecule and is made up of 
the residues 18 to 35, 259 to 309 and 384 to 405. Domain III, which consists of the 
segments 36 to 50 and 181 to 258, is inserted into domain II. Domain III has the 
Pleckstrin homology (PH) domain fold. The only single-segmented domain, the 
domain IV, covers the residues 51 to 181. It is the fusion domain of the molecule 
and makes the stem part.  
 
A: Domain organization in VSV-G monomer. B: VSV-G trimer side view. C: VSV-G trimer viewed 
from the top. D: Regions forming the four domains in VSVG, colored scheme was used for also A-
C. Triangles indicate the glycosylation sites. 
The c-myc epitope insertions were performed at five different positions in the G 
protein of VSV Indiana (Table 11, Figure 38). The modified VSV-G proteins were 
designated according to the number of amino acid in the mature VSV-G protein 
after which the insertion is made. The first insertion was made after the signal 
sequence at position 17. VSV-G myc 17 protein showed intracellular and surface 
staining patterns similar to wild type protein (Figure 13 and Figure 14), which fits 
pretty well the structural data, since domain I was reported to be located on the top 
of the trimer and exposed to the exterior. Amino acid 17 was newly reported to 
tolerate 13 amino acid long epitope and the mutant proteins were incorporated into 
viral particles [150]. Furthermore, in the same study authors could purify retroviral 
particles pseudotyped VSV-G modified at position 17 via Nickel-Nitriltriacetic acid 
(Ni-NTA). We could also demonstrate myc epitope insertion at position 17 gave 
rise to a transport- and fusion-competent mutant (Figure 19). For wild type VSV-G 
optimum pH range is between 5.6 to 6.0 [124]. VSV-G myc 17 has a lower 
A B C
D
  
Figure 37. Domain architecture of the VSV-G low-pH form 
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VSV-G myc 17
VSV-G La 17
VSV-G myc 28
VSV-G La 31
VSV-G myc 208
VSV-G La 209
VSV-G myc 266
VSV-G La 271
VSV-G myc 278
fusogenic activity than VSV-G wt as can be seen from the number and size of the 
syncytia. More to the point, VSV-G myc 17 has a lower optimum pH and a smaller 
pH range for fusion. While VSV-G wt induced membrane fusion at pH 6.0, 
syncytium formation starts with VSV-G myc 17 only at pH 5.5 (Table 14). Thus, the 
10fold lower titer observed with the MLV(G-myc 17) particles is probably due to 
inefficient fusion. The myc epitope insertion at position 17 did not alter the natural 
tropism of VSV-G as seen by the infection of HEK293wt cell. However, when the 
infection was performed in the presence of anti-myc antibodies, VSV-G myc 17-
mediated transduction efficiency was significantly impaired (Figure 27). This 
suggests that a proper linker molecule, which would connect the myc epitope and 
a cellular target may benefit from the reduction of wild type specificity. At this point 
we decided to generate a single-chain antibody fragment against myc epitope to 
use as the linking molecule, such as a diabody, between the modified viral 
particles and the target cells. Unfortunately, we could not obtain scFv molecules 
with binding affinity to myc epitope from the available hybridoma clone (CT9 B7.3) 
(data not shown).  
 
Amino acid numbering corresponds to the mature peptide after the cleavage of 16 amino acid-long 
signal peptide in ER. Secondary structures are: Arrows show ß strands; cylinders indicate helices; 
and dotter lines indicate the disulfide bridges. Picture adopted from Roche et al. [179]. 
Figure 38. Epitope insertion positions in the ectodomain of VSV-G 
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The second insertion was performed at position 28 also in domain I, between the β 
strands a and a’. This modified VSV-G proteins has a temperature-sensitive 
phenotype in which it acts like wild type VSV-G at a permissive temperature 
(Figure 14). The VSV-G myc 28 also exposed the myc epitope on the cell 
membrane in transfected cells and can be used to package retroviral particles 
(Figure 15). However, at restrictive temperature (37°C) VSV-G myc 28 is detected 
only in perinuclear compartments. It has been shown that epitope insertion at 
position 24 [147] also exhibited temperature-sensitive phenotype. In the 
interpretation of the domains in the VSV-G, Roche et al. [179] described that the ß 
strands a and a’ is wrapped by the three antiparallel ß sheets forming the domain 
I. since position 28 corresponds to the region prior to ß strand a’, it is highly 
probable that such an insertion interferes with the correct folding. At the 
permissive temperature VSV-G myc 28 was fusogenic albeit not as efficient as 
VSV-Gwt or VSV-G myc 17 (Figure 19). VSV-G myc 28-mediated membrane 
fusion resulted in small syncytia and fusion was observed only at pH 5.5 (Table 
14). 
Next, two insertions at positions 208 and 266 were made. Both positions reside in 
the domain III. Domain III contains a typical Pleckstrin Homology (PH) domain. PH 
domain-containing proteins can bind to phosphatidylinositol lipids in the 
membranes, which suggest that this domain may play an important role in 
interactions with the membrane [180,181]. In the low-pH conformation of VSV-G 
domain III is located in the interior of domain II, which renders this domain 
inflexible in accommodation of additional sequences. This may explain why the 
insertion mutants at positions 208 and 266 are not transported beyond the 
perinuclear areas (Figure 13 and Figure 14). Furthermore, in the mature protein 
there is a disulfide bridge between residues C219 and C253 and the insertion at 
position 266 (in precursor protein; in the mature protein position 250) may inhibit 
this interaction. This position was recently shown to be intolerant even to smaller 
epitope (six amino acid long) by Schlehuber and Rose [147]. 
The last myc epitope insertion was made at position 278. This mutant displayed 
wild type surface expression characteristics (Figure 14). Also the myc epitope was 
readily detectable on natively stained cells (Fig.16). However, this mutant failed to 
induce any membrane fusion (Figure 19). Position 278 is located in the beginning 
of helix F in the domain II, which is responsible for the trimerization of the protein. 
During the conformational changes in fusion helix F undergoes major refolding and 
re-organization (Figure 39). These re-positioning events also include amino acid 
residues that are very close to the insertion at position 278 (Figure 39). Therefore 
it is possible that the insertion does not affect the initial folding and transport of the 
protein to the cell membrane, but at low-pH this insertion inhibits the necessary 
conformational changes.  
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In conclusion, we have identified two epitope insertion sites in the VSV-G protein, 
which are successfully incorporated into retroviral particles. The myc epitope 
enabled the purification of MLV(G-myc 17), and MLV(G-myc 28) particles from the culture 
medium (Figure 24). This suggests an alternative to the recently published 
purification via the His-tag [150]. Moreover, we demonstrated with anti-myc 
antibody selective inhibition of MLV(G-myc 17), and MLV(G-myc 28).  
 
A: The pre- and post-fusion conformation of the hinge region between the domains III and IV. B: 
Refolding of domain II during the fusion. Description of domains. C: Reorganization of domains in 
the VSV-G protein and their relative positions in the pre- and post-fusion states [2], domains were 
colored as in Figure 37.  
7.1.3. Generation of La epitope modified VSV-G proteins 
The lack of functional scFv against the myc epitope, which can be used for 
generation of bispecific diabodies, we included the La epitope into our analyses. In 
our institute, scFv molecules against La epitope are already available. Insertion of 
La epitope into the ectodomain of VSV-G was performed at four different positions, 
close to myc epitope insertion positions (Table 11). The insertions were localized 
Figure 39. Conformational changes in the ectodomain of VSV-G protein during low pH-
induced fusion [2]. 
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to three domains in the protein. Two of the La mutants were transported to the cell 
membrane but only one exposed the epitope (Figure 16, Figure 17 and Figure 18). 
Insertion at position 17 (in precursor protein) locates to domain I. This mutant was 
only detectable in permeabilized cells at 37°C and was not transported to the cell 
surface. The low level of expression and the failure in transport to the plasma 
membrane with this La mutant implies the importance of epitope length that can be 
tolerated at a certain position.  
The second La epitope insertion was made at position 31, which corresponds to 
position 17 in the mature protein and lies in domain II (Figure 38). This mutation is 
located in the N-terminal part of the first segment that belongs to domain II. 
Although in the crystal structure this position seems to be in a relatively free 
position, it may have interfered with correct folding and subsequent trimerization of 
VSV-G. 
The last two insertions were performed positions residing in domain III. Mutants 
with La epitope at positions 209 and 271 were produced by the transfected cells 
though at lower levels than VSV-G wt (Figure 16). And interestingly both mutant 
proteins were detected with anti-VSV-G antibody recognizing the external epitope 
although this domain is hidden in the domain II and insertion of the small myc 
epitope in very close positions interfered with the transport (Figure 17). A possible 
explanation may be the flexibility gained by the insertion of a longer epitope. The 
myc epitope may introduce a stretch of amino acids which sterically hinders 
correct folding, but it is possible that the two times longer La epitope gave enough 
flexibility by looping out and leaving the domain more or less intact. This is also 
supported by the detection of La epitope in native staining on VSV-G La 271-
transfected cells (Figure 18). It is likely that the location of La epitope relative to 
the insertion position, which has to form a loop, is also important since VSV-G La 
209 did not expose the epitope. These two mutations also confirm the important 
role of the introduced epitope length.  
Finally, the fusion activity of La-modified VSV-G protein, which was expressed on 
the cell surface and exposed La epitope, was analyzed (Figure 20). In the fusion 
assay, pH values between 5.0 and 7.5 were tested but VSV-G La 271 failed to 
induce any fusion. This position is close to the ß-sheet “q” which re-positions itself 
in the last steps of conformational changes during fusion and may therefore hinder 
the re-organization necessary to achieve a fusion active state. 
7.1.4. Conclusion of mutational analysis of VSV-G 
VSV-G protein production is tightly controlled and therefore the protein does not 
contain many permissive sites for modifications. VSV-G still possesses several 
advantages as a pseudotyping envelope protein over other viral proteins. However 
the main drawback, the ubiquitous infection mediated by VSV-G must be restricted 
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to the target cells in order to exploit the potential of VSV-G. Therefore ligand-
modification of VSV-G is an interesting and exciting area. Unfortunately the 
intensive intramolecular interactions set hurdles to the selection of the insertion 
permissive regions. Together with the recently published crystal structures of pre- 
and post-fusion conformations of VSV-G our results point out two suitable sites for 
targeting of VSV-G pseudotyped particles to a defined cell type. As it has been 
shown also by other groups, the N-terminal region of VSV-G is permissive to 
epitope insertions [147,149,150]. It is interesting that within a very small region of 
amino acid residues 24-28 in the precursor protein, two different populations of 
mutant VSV-G proteins were obtained. The first population had the wild type 
characteristics and was transported to the membrane at 37°C, whereas the 
second population displayed temperature-sensitive phenotype that can be rescued 
at permissive temperature. This underscores the importance of precise location of 
the epitope inserted into VSV-G.  
A major problem with ligand-modified VSV-G-pseudotyped particles is the 
inefficient transduction. This is mainly due to the reduced fusion capacity of the 
mutant VSV-G proteins. This appears to be an ordinary problem of viral particles. 
Tai et al. overcame this problem with ecotropic and amphotropic MLV vectors 
modified by insertion of ZZ domain in the envelope protein by co-expressing the 
wild type envelope protein [108]. In case of VSV-G this strategy may result in the 
loss of ligand-specificity and therefore must be considered with care. And yet it will 
be interesting to see the capacity of fusion-defective mutant VSV-G myc 278 to 
target retroviral particles in the presence of a fusion-competent envelope.  
In conclusion, the two positions we have chosen (positions 17 and 28) regarding 
the sequence difference between VSV strains appear plausible for modifications 
studies also according to the crystal structure elucidated in 2006. Since the VSV-G 
undergoes an extensive series of re-folding and domain organizations, these two 
positions, which locate to the free N-terminal part of the protein prove to be 
suitable modification sites. 
7.1.5. Outlook into nanotechnology 
Although we have functional scFv against the La epitope, none of our mutants 
induced fusion. Thus, we have turned our attention to the myc mutants and 
decided to analyze them for regarding the purification of viral particles and 
targeted transduction of PSCA-positive cells using nanoparticles coupled to 
antibodies.  
Nanotechnology has long being used in gene delivery by gene bombarding. The 
advancements in bioengineering also allowed modification of this technology to 
make it more specific, in which ligand molecules were incorporated into the matrix 
of nanoparticles. VSV-G proteins modified at amino acid positions 17 and 28 are 
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suitable targets for ligand-directed gene delivery. In order to gain a standpoint on 
the benefits of these mutants nanoparticles chemically coupled to anti-PSCA and 
anti-myc antibodies were used. The idea behind is to capture myc-modified 
retroviral particles via the anti-myc antibodies and to connect them to PSCA-
expressing target cells using anti-PSCA antibodies. For this purpose, first of all it is 
necessary to demonstrate binding of both moieties to their respective ligand. This 
was achieved for PSCA by incubating PSCA-positive and PSCA-negative cells 
with nanobeads and then detecting the antibodies coupled to nanobeads with a 
secondary anti-mouse antibody (Figure 28). After showing the binding to the target 
cells, we evaluated the effect of nanobeads on the survival of cells. In an 
apoptosis assay we confirmed that upon binding and internalization nanobeads do 
not induce apoptosis of PSCA-positive and of PSCA-negative cells (Figure 29). 
Next, binding of nanobeads to modified retroviral particles was analyzed with a 
simple capture assay. MLV(G-wt), MLV(G-myc 17), and MLV(G-myc 28) particles were 
incubated in the presence of nanobeads and the complex was then precipitated. In 
Western blot analysis we could show precipitation of myc-modified particles, which 
were detected by using an anti-MLV capsid serum (Figure 30). As expected 
MLV(G-wt) particles were not precipitated.  
MLV(G-wt) particles were used for transduction of HEK293wt cells in the presence 
or absence of nanobeads and as expected transduction efficiencies were 
comparable (Figure 31). Thus nanobeads exert no unspecific adverse effect on 
the transduction when viral particles and the target cells display no binding 
partner. In case of transduction of PSCA-positive cells (Figure 32) a small 
decrease in efficiency was observed with MLV(G-wt) particles in the presence of 
nanobeads, which may due to the binding of nanobeads onto PSCA-positive cells 
and reduce the available surface area that can interact with the viral particles. 
When MLV(G-myc 17) particles were used for transduction in the excess of 
nanobeads, we observed an inhibition similar to that seen with anti-myc antibody 
(Figure 34). And there was no significant increase in the specificity of transduction 
was observed when PSCA-positive cells were used (only 4% increase). These 
results contradict the outcomes of a recent report by Chan et al. [155]. They have 
demonstrated an effective concentration and purification of biotinylated lentiviral 
vector via streptavidin-coated nanoparticles where the nanoparticles were at least 
103 in excess of the viral particles. We assume that an overload of nanoparticles 
will cover the surface of the viral particles. Such masked particles would never get 
in contact to the cellular membranes (Figure 40). Therefore, the viral envelope is 
not capable of undergoing the structural changes necessary for the fusion.  
And yet the results are encouraging because by optimizing the virus-capture 
conditions for VSV-G myc 17, targeted transduction of PSCA-positive cells can be 
achieved. It may be worthwhile to titrate more precisely the number of viral 
particles that can be bound to a single nanobead to enable effective binding onto 
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PSCA-positive cells via the anti-PSCA antibody. Moreover, as shown by Capra 
and Ednumdson [182], antibody molecules are very small in size compared to the 
viral particles and the nanobeads (Figure 41). When the viral particle binds to the 
nanobead via antibody recognizing the modified envelope protein, the second 
antibody recognizing the target antigen on the tumor cells may not be able to 
contact the TAA. Thus it may also be useful to anchor target antigen-binding 
antibodies onto the nanobeads via bigger hinge regions to allow better projection 
of these molecules towards the target cells.  
 
a: anti-PSCA antibody; b: anti-myc antibody; c: the nanobead; d: the modified viral 
particle; e: nanobead coupled to anti-myc and anti-PSCA antibodies; f: complex 
formation in the excess of nanobeads; g: complex formation in the excess of viral 
particles. 
Figure 40. Complex formation between the nanobeads and the viral particles. 
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A: Electron microscope picture of antibody molecules bound to viral particles. B. Illustration of 
antibody molecules bound to a viral particle regarding the size [182] 
Another approach to use the epitope-modified VSV-G mutants is to generate 
bispecific diabodies. Diabodies are antibody fragments composed of two single-
chain antibody fragments. It is possible to generate diabodies which bind with one 
scFv part to the epitope on the viral envelope protein, and with the other scFv to 
the tumor associated antigen on the tumor cells (Figure 42). This allows direct 
targeting of the viral particle. Moreover, diabodies lack the Fc region of the 
parental antibody and therefore may be particularly useful in clinical applications 
since they avoid the host immune response against the Fc-portion.  
 
Figure 41. Antibody molecules bound to a virus. 
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scFv against the myc epitope in the VSV-G (A) and PSCA (B) can be fused to generated a 
bispecific diabody (C). This diabody is capable of recognizing the PSCA (D) and recruiting the 
modified viral particle (E) to the tumor cells for a targeted anti-tumor therapy (F).  
An alternative strategy involves the over-expression of the linker molecule such as 
the scFv recognizing the TAA in the packaging cell line. As shown by Chan et al., 
viral particles gather the proteins expressed on the packaging cell membrane 
during the budding process. These proteins are then available for a targeting 
procedure. For instance, the scFv anti-PSCA can be over-expressed on the 
packaging cell line. Thus, we can generate retroviral particles, which contain the 
myc-modified VSV-G protein for purification and the scFv anti-PSCA for the 
targeting. Expression of the scFv as a separate membrane protein instead of a 
fusion moiety to the VSV-G overcomes the problems in the folding and fusion 
therefore allows the production of fully functional VSV-G proteins. Anchoring the 
scFv to a hinge region for a better projection should facilitate the target antigen 
binding. 
 
BA C D E
Tumor cell
F
Normal cell
Figure 42. Targeting strategy with bispecific diabodies 
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8. CONCLUSION 
As to our knowledge, up to now, there only few successful modifications of VSV-G 
protein, which confined the specificity [146,147,149]. However, in these studies the 
mutant VSV-G proteins lacked the wild-type fusion or packaging capacity. Thus, 
although in both studies specific binding was demonstrated, the transduction 
levels were insufficient. In another recent report, His-tag was inserted into the 
VSV-G and these mutants were successfully incorporated into viral particles, 
which in turn were purified via Ni-NTA chromatography. Unfortunately, the mutant 
protein retained the wild-type tropism and is therefore is not applicable for targeted 
therapy. On the other hand, our mutational analyses have revealed two epitope-
permissive sites in the ectodomain of VSV-G protein, which allows viral assembly 
and purification using antibodies. This suggests an alternative to the recently 
published purification via the His-tag [150]. The fact that the MLV(G-myc 17), and 
MLV(G-myc 28) mediated transductions were inhibited by anti-myc antibody and 
increased transduction efficiency on PSCA-positive cells with these particles 
implies their potential as targeting vectors.  
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pAMI-G
7853 bp
Amp(R)
Neo(R)
myc
AMI
VSV-G (-LS)
SV40 pA
BGH pA
BGH reverse primer
CMV forward primer
T7 primer
CMV promoter
SV40 early promoter
bla promoter
T7 promoter
f1 origin
pUC origin
 
pAMI-L-G
7868 bp
Amp(R)
Neo(R)
AMI
Linker
myc
VSV-G (-LS)
SV40 pA
BGH pA
BGH reverse primer
CMV forward primer
T7 primer
CMV promoter
SV40 early promoter
bla promoter
T7 promoter
f1 origin
pUC origin
 
pAMI-L-sG-1
7533 bp
Amp(R)
Neo(R)
AMI
Linker
myc
truncated VSVG-fuso2
SV40 pA
BGH pA
BGH reverse primer
CMV forward primer
T7 primer
CMV promoter
SV40 early promoter
bla promoter
T7 promoter
f1 origin
pUC origin
linker-fuso
 
10. APPENDIX  
10.1. Vector maps 
pAMI-G  
pAMI-L-G  
pAMI-L-sG1  
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pAMI-L-sG-2
7380 bp
Amp(R)
Neo(R)
AMI
Linker
myc
truncated VSV-G fuso-3
SV40 pA
BGH pA
BGH reverse primer
CMV forward primer
T7 primer
CMV promoter
SV40 early promoter
bla promoter
T7 promoter
f1 origin
pUC origin
linker-fuso
 
pcz-VSV-Gwt
6691 bp
VSV-G
Zeo(R)
Amp(R)
BGH pA
CMV
SV40 early promoter
pUC origin
f1 origin
 
pAMI-L-sG2  
pcz-VSV-Gwt  
pcz-VSV-G myc 17  
pcz-VSV-G myc 28  
pcz-VSVG-myc-17
6724 bp
VSV-G mod.
Zeo (R)
Amp (R)
myc epitope
BGH pA
SV40 early promoter
CMV
f1 origin
pUC origin
 
pcz-VSVG-myc-28
6724 bp
VSV-G
Zeo(R)
Amp(R)
myc
BGH pA
CMV
SV40 early promoter
pUC origin
f1 origin
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pcz-VSVG-myc-208
6724 bp
VSV-G
Zeo(R)
Amp(R)
myc epitope
BGH pA
CMV
SV40 early promoter
pUC origin
f1 origin
 
pcz-VSVG-myc 266
6724 bp
VSV-G
Zeo(R)
Amp(R)
myc epitope
BGH pA
CMV
SV40 early promoter
pUC origin
f1 origin
 
pcz-VSVG-myc 278
6724 bp
VSV-G
Zeo(R)
Amp(R)
myc epitope
BGH pA
CMV
SV40 early promoter
pUC origin
f1 origin
 
pMD2.G VSV-G
5824 bp
VSV-G
Amp
beta-globin intron
beta-globin pA
CMV
pUC
 
pcz-VSV-G myc 208   
pcz-VSV-G myc 266  
pcz-VSV-G myc 278  
pMD.G2  
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pMD.G2-La 17
5881 bp
VSV-G
VSV-G B4
Amp
beta-glo bin  in tron
4B6 XVIII B4
beta-glo bin  pA
C MV
pU C
Av a I
C laI
H indIII
Ps t I
Xho I
Age I
Apa LI
ApaLI
Ec oR I
Ec o R I
BamH I
BamH I
BamH I
N c oI
N c oI
N c oI
 
pMD.G2-La 31
5881 bp
VSV-G
Amp
beta-globin intron
La
beta-globin pA
CMV
pUC
 
pMD.G2-La 209
5881 bp
VSV-G
Amp
beta-globin intron
4B6 XVIII B5
beta-globin pA
CMV
pUC
 
pMD.G2-La 271
5881 bp
VSV-G
Amp
beta-globin intron
4B6 XVIII B3beta-globin pA
CMV
pUC
 
pMD.G2-La 17   
pMD.G2-La 31  
pMD.G2-La 209  
pMD.G2-La 271  
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